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Izvleček 
Uvod: Amiotrofična lateralna skleroza (ALS) je smrtonosna napredujoča 
nevrodegenerativna bolezen, za katero so značilni citoplazemski skupki proteinov v 
prizadetih nevronih. Glavna komponenta teh inkluzij je ubikvitiniran, fosforiliran in cepljen 
protein TDP-43. Primerov ALS z mutacijami v genu je TDP-43 zelo malo, kar pomeni, da ima 
TDP-43 v patoloških agregatih pri večini pacientov povsem običajno zaporedje. Vedno več 
raziskav nakazuje, da imajo citoplazemski skupki TDP-43 lastnosti podobne prionskim 
proteinom. Zanje je značilno sejanje agregatov in njihovo širjenje med celicami in vitro in in 
vivo, novejše študije pa so identificirale tudi različne tipe agregatov pri bolnikih z ALS in 
frontotemporalno demenco (FTD). Alternativne patološke konformacije agregatov bi lahko 
podobno kot sevi prionskih proteinov, bile osnova za raznolikost proteinopatij TDP-43 in 
heterogenost bolezni. Raziskovalne skupine so poleg TDP-43 identificirale že več kot 50 
genov, ki povzročajo ali vplivajo na nastanek ALS in so vključeni v dve skupini celičnih 
procesov: metabolizem RNA in razgradnja proteinov. Pri tem pa vloga drugih genov, 
povezanih z ALS in njihovih mutacij na agregacijo TDP-43, ostaja neznanka.  
Namen dela in hipotezi: V pričujoči študiji smo primerjali vpliv več mutiranih in 
nemutiranih genov, povezanih z ALS, na agregacijo TDP-43 in biokemijske lastnosti 
agregatov in vitro. Hipotezi, na katerih sloni raziskava, se osredotočata na dva vidika 
agregacije proteina TDP-43 - na vpliv genov povezanih z ALS na agregacijo TDP-43 in na 
citoplazemsko lokalizacijo agregatov TDP-43: Izražanje z ALS povezanih genov (UBQLN2, 
MATR3, VCP, hnRNPA1) vpliva na biokemijske lastnosti in/ali celično lokalizacijo proteina 
TDP-43. Modeliranje okvar jedrno-citoplazemskega transporta v celicah zaostri patološke 
spremembe, ki so posledica izražanja posamezne mutacije povezane z ALS. 
Metode dela:  Da bi raziskali oba vidika nastanka agregatov TDP-43 smo najprej razvili nov 
in vitro model agregacije TDP-43 v celični liniji SH-SY5Y. Okvare jedrno-citoplazemskega 
transporta TDP-43 smo modelirali z eliminacijo signala za jedrno lokalizacijo (NLS) in s tem 
premaknili TDP-43 iz jedra v citoplazmo. Nato smo postopoma skrajševali LCD proteina in s 
tem zmotili fiziološko konformacijo dimerov TDP-43. Pri ko-transfekcijskih eksperimentih, s 
katerimi smo želeli preveriti vpliv prej naštetih mutiranih in nemutiranih z ALS-povezanih 
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genov na agregacijo TDP-43, smo uporabili celoten TDP-43 z odstranjenim NLS (dNLS) in 
TDP-43 brez NLS in IDR2 (dNLSd343). Nastanek agregatov v kotransfeciranih celicah smo 
kvantificirali s konfokalno mikroskopijo in nadalje analizirali s programom ImageJ z dodanim 
vtičnikom Shape Descriptors. Topnost oziroma netopnost agregatov v pufrih RIPA in UREA 
smo analizirali s prenosom western. 
Rezultati in razprava: Pokazali smo, da krajšanje domene LCD vodi do različnih vzorcev 
agregacije TDP-43. S ko-transfekcijo konstruktov dNLS in dNLSd343 z mutiranimi in 
nemutiranimi z ALS-povezanimi geni smo pokazali, da ima vsak izmed testiranih genov 
edinstven vpliv na vzorec agregacije TDP-43 in na topnost agregatov. Te učinke smo 
preučevali v kontekstu okvarjenega nukleocitoplazemskega transporta, ki je zaostril 
patološko agregacijo v celicah ko-transfeciranih z mutiranimi ali nemutiranimi z ALS-
povezanimi geni. Nekateri geni, kot sta na primer mutirani in nemutirani hnRNPA1 so 
zmanjšali število agregatov in povečali njihovo topnost, drugi pa so povečali število agregatov 
in/ali njihovo velikost in/ali zmanjšali njihovo topnost. Pokazali smo tudi, da vsak izmed 
genov edinstveno vpliva tako na dNLS kot na dNLSd343, kar kaže na pomembno vlogo 
skrajnega C-končnega dela domene LCD pri nastanku in maturaciji agregatov. Izsledki naše 
študije tako potrjujejo, da vsak izmed z ALS-povezanih genov, ki smo jih raziskovali, 
edinstveno vpliva na procese agregacije TDP-43, kar vodi do nastanka različnih »tipov 
agregatov,« ki bi lahko predstavljali temelj za heterogenost bolezni ALS. 
Zaključki in znanstveno-raziskovalni pomen študije: Študija, predstavljena v tej 
doktorski disertaciji je prva, ki primerja vpliv z ALS-povezanih genov na agregacijo proteina 
TDP-43. V sklopu študije smo tudi razvili model agregacije proteina TDP-43, s katerim bi 
lahko v prihodnosti raziskovali zmožnost potencialnih terapevtskih učinkovin za zmanjšanje 
ali eliminacijo agregatov TDP-43 in s tem izboljšanje patoloških sprememb v prizadetih 
celicah bolnikov z ALS. Naši rezultati potrjujejo potrebo po primerjalnih raziskavah na 
področju ALS in razkrivajo, kako različni mehanizmi interagirajo na molekulskem nivoju in 
vodijo v nevrodegeneracijo, kar se bo morda izkazalo kot ključnega pomena za uspešen 
razvoj terapevtikov. 
Ključne besede: ALS; TDP-43; hnRNPA1; MATR3; VCP; UBQLN2; citoplazemska agregacija; 
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Abstract 
Introduction: ALS is a fatal progressive neurodegenerative disease pathologically 
characterized by cytoplasmic deposits of misfolded proteins in the affected neurons. The 
main component of these inclusions is ubiquitinated, phosphorylated and cleaved TDP-43 
protein. Mutated TDP-43 is very rare, meaning that most of the patients with TDP-43 positive 
aggregates do not carry any mutation in this protein. Mounting evidence suggests that 
cytoplasmic accumulations of TDP-43 exhibit prion-like characteristics. In addition to 
seeding and intercellular propagation of TDP-43 aggregation between cells in vitro and in 
vivo, different types of the TDP-43 aggregates in ALS and FTD diseased brains have been 
identified. It has been proposed, that alternate pathological conformations may form the 
basis for the diversity of TDP-43 proteinopathies and disease heterogeneity, reminiscent of 
prion strains. So far, more than 50 potentially causative or ALS-modifying genes have been 
identified, mainly involved in two cellular processes: RNA metabolism and quality control of 
protein metabolism. However, the role of ALS-associated genes, the possible impact of their 
mutations on TDP-43 aggregate behavior and properties remains largely unknown. 
Aim and Hypotheses: In this study, we sought to compare the impact of several wild-type 
and mutated ALS-associated genes on TDP-43 aggregation in vitro. Our hypotheses focused 
on two aspects of TDP-43 aggregation. On the impact, ALS-associated genes display on TDP-
43 aggregation and on the cytoplasmic localization of TDP-43 aggregates. Expression of 
genes (UBQLN2, MATR3, VCP and hnRNPA1) linked to ALS affects biochemical properties 
and/or cellular localization of protein TDP-43. Nucleo-cytoplasmic transport defect 
modelling exacerbates pathological changes resulting from the expression of a certain ALS 
mutation.  
Methods: To explore both aspects of TDP-43 aggregation, we first developed a novel in vitro 
TDP-43 aggregation model in neuroblastoma SH-SY5Y cell line. To model defects of nucleo-
cytoplasmic transport and achieve TDP-43 cytoplasmic localization, we eliminated NLS from 
the full-length TDP-43 sequence. Then we stepwise shortened its LCD, to disrupt 
physiological conformation of TDP-43 dimers. Full-length TDP-43 lacking only NLS (dNLS) 
and TDP-43 without NLS and IDR2 (dNLSd343) constructs were used in co-transfection 
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experiments to assess the impact of pre-selected wild-type and mutant ALS-associated genes 
on TDP-43 aggregate behavior. Aggregate formation in co-transfected cells was quantified by 
confocal microscopy and further analyzed by ImageJ software with Shape Descriptors plugin. 
Solubility and insolubility of the aggregates in UREA and RIPA buffers was analyzed by 
western blotting. 
Results and Discussion: We demonstrated that shortening of the LCD domain leads to 
distinct patterns of TDP-43 aggregation. By co-transfecting dNLS and dNLSd343 constructs 
with wild-type and mutant ALS-associated genes, we demonstrated that each of the tested 
genes has a unique influence on TDP-43 aggregation pattern and solubility of the aggregates. 
These effects were studied in the context of disrupted nucleocytoplasmic transport, which 
caused exacerbation of pathological aggregation following co-transfection with wild-type or 
mutant ALS-associated genes. While some of the ALS-associated genes, such as wt and mut 
hnRNPA1 reduced the number of aggregates and increased their solubility, others increased 
the number of aggregates and/or their size and/or decreased their solubility. We also show 
that each of the genes has a unique influence on both dNLS and dNLSd343, suggesting that 
the extreme C-terminus has a prominent role in initiation and maturation of the aggregates. 
Considering all this data, we propose that each ALS-linked gene we studied uniquely affects 
TDP-43 aggregation processes, leading to the formation of distinct “aggregate types,” which 
could represent the basis for the disease heterogeneity. 
Conclusions: The study presented in this doctoral dissertation is first to provide an insight 
into the impact ALS-associated genes have on TDP-43 aggregation. Additionally, as a part of 
our research, we developed a TDP-43 aggregation model, which could be used in future 
studies of therapeutic compounds with a potential to reduce or eliminate TDP-43 aggregates 
and thus reverse pathological changes in the affected cells of ALS patients. Our results also 
emphasize the significance of comparative research in the ALS field and provide an 
understanding on how different mechanisms interact at the molecular level and lead to 
neurodegeneration that may reveal crucial in the future for successful development of 
therapeutics. 
Keywords: ALS; TDP-43; hnRNPA1; MATR3; VCP; UBQLN2; cytoplasmic aggregation; 
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1. Povzetek v slovenskem jeziku 
1.1. Pregled literature 
Amiotrofična lateralna skleroza (ALS) je smrtonosna napredujoča nevrodegenerativna 
bolezen, za katero so značilni citoplazemski skupki proteinov v prizadetih nevronih. Glavna 
komponenta teh inkluzij je ubikvitiniran, fosforiliran in cepljen protein TDP-43 (Neumann et 
al. 2006). V fizioloških pogojih je TDP-43 pretežno jedrni protein, vključen v različne procese 
metabolizma RNA. Sestavljajo ga N-končna domena, povezana z oligomerizacijo, klasični 
dvostranski signal za jedrno lokalizacijo (NLS), dva RNA-prepoznavna motiva (RRM1 in 
RRM2) in domena z nizko kompleksnostjo (LCD) (Loughlin and Wilce 2019). Kljub temu da 
je od 5 do 10 % primerov ALS je podedovanih, je primerov z mutacijami v genu TDP-43 zelo 
malo, kar pomeni, da ima TDP-43 v patoloških agregatih pri večini pacientov povsem 
običajno zaporedje (Sreedharan et al. 2008; Nishimura et al. 2014; Hergesheimer et al. 2019). 
Raziskovalne skupine so poleg TDP-43 identificirale že več kot 50 genov, ki povzročajo ali 
vplivajo na nastanek ALS in so vključeni v dve skupini celičnih procesov: metabolizem RNA 
in razgradnja proteinov (Sreedharan et al. 2008; Vance et al. 2009; Maruyama et al. 2010; 
Deng et al. 2011; 2011; Kim et al. 2013; van Rheenen et al. 2016; Mackenzie et al. 2017). Zdi 
se, da imata tako kopičenje nepravilno zvitih proteinov kot pomanjkljiva razgradnja podobno 
škodljiv vpliv, kar nakazuje na skupno patogeno kaskado (Mandrioli et al. 2020). Kljub temu 
pa je za nastanek in napredovanje bolezni verjetno odgovoren preplet genetskih in okolijskih 
dejavnikov (Nowicka et al. 2019). 
V zadnjem času se vedno bolj uveljavlja mišljenje, da je v agregacijo RNA-vezavnih proteinov, 
kot je TDP-43, vpletena fazna separacija tekoče-tekoče (LLPS). LLPS naj bi deloval kot začetni 
mehanizem nastanka agregatov, ki nato delujejo kot matrica za nadaljnje rekrutiranje 
proteinov divjega tipa, kar nazadnje vodi do nastanka ireverzibilnih inkluzij, značilnih za 
nevrodegenerativne bolezni (Babinchak and Surewicz 2020). Glavno gonilo LLPS proteinov 
so domene LCD in RRM (Gomes and Shorter 2019). Eden izmed proteinov, ki je preko svoje 
domene LCD podvržen LLPS, je tudi TDP-43 (Molliex et al. 2015; Babinchak and Surewicz 
2020). Njegovo domeno LCD se lahko razdeli na tri segmente: dve notranje neurejeni regiji 
(IDR1 in IDR2), med katerima je ohranjena regija (CR), ki rada zavzame α-vijačno zvitje 
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(Schmidt, Barreau, and Rohatgi 2019). Gonilo LLPS proteina TDP-43 so verjetno hidrofobne 
medmolekulske interakcije med α-vijačnimi regijami (Conicella et al. 2016; Li et al. 2018; 
Schmidt, Barreau, and Rohatgi 2019). Vloga N-končne domene pri agregaciji TDP-43 je 
nekoliko kontroverzna: nekatere študije trdijo, da oligomerizacija TDP-43 preko N-končne 
domene omogoča interakcije z drugimi partnerski proteini in RNA in s tem preprečuje 
nastanek patoloških agregatov, druge pa nakazujejo, da poveča zmožnost agregacije 
notranje-neurejene C-končne regije (Afroz et al. 2017; Tsoi et al. 2017). Pokazali so tudi, da 
motnje v N-končni regiji zmanjšajo zmožnost proteina TDP-43 za LLPS in nastanek agregatov 
(Zhang et al. 2013; A. Wang et al. 2018). Visoko ohranjene domene RRM proteina TDP-43 pa 
vežejo enojne verige DNA in RNA, kar poveča njegovo topnost in prepreči nastanek agregatov 
(Huang et al. 2013; Sun et al. 2014; Solomon et al. 2018; Mann et al. 2019; French et al. 2019). 
 Za citoplazemske skupke TDP-43 se vedno bolj uveljavlja prepričanje, da imajo lastnosti 
podobne prionskim proteinom (Nonaka and Hasegawa 2020). Za prionom podobne proteine 
je značilno sejanje agregatov v celicah z nativnimi proteini in njihovo širjenje med celicami in 
vitro in in vivo. Novejše študije so identificirale tudi različne tipe agregatov pri bolnikih z ALS 
in FTD, ki spominjajo na prionske seve (Furukawa et al. 2011; Nonaka et al. 2013; Smethurst 
et al. 2016; Porta et al. 2018; Laferrière et al. 2019). Različne patološke konformacije 
agregatov bi lahko, podobno kot sevi prionskih proteinov, bile osnova za heterogenost 
proteinopatij TDP-43 in raznolikost poteka bolezni (Laferrière et al. 2019).  
1.1.1. Heterogeni jedrni ribo-nukleoprotein A1 (hnRNPA1)  
Kot TDP-43 je tudi hnRNPA1 član družine hnRNP in sicer poddružine A/B (Bekenstein and 
Soreq 2013). Člani te proteinske družine so skupaj s histoni najbolj zastopani proteini v jedru 
(Bekenstein and Soreq 2013). Zaradi svoje strukture lahko interagirajo tako s proteini kot z 
RNA, kar jim omogoča vključitev v procese izrezovanja intronov, stabilizacije mRNA, 
biogeneze miRNA in regulacije transkripcije (Bekenstein and Soreq 2013; Roy et al. 2017; 
Howard et al. 2018). HnRNPA1 je 34 kDa velik protein, sestavljen iz dveh domen RRM in z 
glicinom bogate regije na C-končnem delu, ki vsebuje zaporedje M9 (aminokisline 268 do 
305), vključeno v transport med jedrom in citoplazmo (Bekenstein and Soreq 2013; Roy et 
al. 2017). HnRNPA1 se prenaša v jedro z vezavo na karioferin β2 (transportin-1) in 
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fosforilacija serinskega preostanka v neposredni bližini zaporedja M9 vodi do citoplazemske 
akumulacije hnRNPA1 (Allemand et al. 2005; Twyffels, Gueydan, and Kruys 2014). C-končna 
regija pa je vključena v medsebojne interakcije proteinov hnRNP. C-končni del proteina TDP-
43 tako neposredno interagira s C-končnim delom proteina hnRNPA1 in s tem tvori 
kompleks, ki je vključen v regulacijo izrezovanja intronov (Buratti et al. 2005).  
Leta 2013 so odkrili mutacijo D262V v prionom podobni regiji zaporedja za hnRNPA1, ki 
povzroča multisistemsko proteinopatijo in ALS z avtosomno-dominantnim dedovanjem (Kim 
et al. 2013). V prizadetem tkivu mišic agregati proteina TDP-43 delno ko-lokalizirajo s 
hnRNPA1 (Kim et al. 2013). Kljub zmanjšanim nivojem hnRNPA1 v motoričnih nevronih s 
citoplazemskimi agregati TDP-43, v inkluzijah niso zaznali prisotnosti hnRNPA1 (Honda et 
al. 2015). 
1.1.2. Matrin-3 (MATR3) 
Matrin-3 je 125 kDa velik protein notranjega dela jedrnega matriksa. Vsebuje številne motive, 
vključno z dvema domenama RRM, dvema motivoma cinkovega prsta (Znf), NLS in NES (Zhao 
et al. 2018). Proteini jedrnega matriksa tvorijo skeletno jedrno ogrodje in so vključeni v 
organizacijo kromatina, podvojevanje, prepisovanje in popravilo DNA ter procesiranje in 
transport RNA (Belgrader, Dey, and Berezney 1991). Matrin-3 se skupaj s proteinoma SFPQ 
in NONO aktivira v odgovor na poškodbe DNA (Salton et al. 2010), vključen je v stabilizacijo 
mRNA (Salton et al. 2011), regulira alternativno izrezovanje intronov (Coelho et al. 2015; 
Attig et al. 2018) in se fosforilira kot odgovor na aktivacijo N-metil-D-aspartatnega receptorja 
(NMDAR) (Giordano et al. 2005).  
Mutacijo S85C v genu MATR3 so najprej povezali z avtosomno-dominantno distalno 
miopatijo (Senderek et al. 2009). Leta 2014 pa so na podlagi izsledkov sekvenciranja 
eksomov mutacije v MATR3 reklasificirali v familiarno obliko ALS (fALS) (Johnson et al. 
2014). Inkluzije proteina matrin-3 so našli v nekaterih prizadetih nevronih pacientov, 
vključno s tistimi z mutacijo v genu C9orf72 namesto v MATR3 (Johnson et al. 2014). 
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1.1.3. Valosin-containing protein (VCP) 
VCP ali p97 je član družine AAA+ ATPaz (ATPases associated with diverse cellular activities). 
To je velika in raznolika naddružina proteinov, ki jih lahko najdemo v vseh organizmih in 
opravljajo široko raznolike aktivnosti. Energijo, ki se sprosti ob hidrolizi ATP, uporabijo kot 
gonilno silo za preoblikovanje strukture molekul (Snider, Thibault, and Houry 2008). VCP 
ima obliko β-sodčka, sestavljeno iz dveh homo-heksamernih obročev in po hidrolizi ATP eden 
izmed njiju dramatično spremeni konformacijsko obliko (Xia, Tang, and Ye 2016). Protein 
VCP je močno ohranjen od arhej do ljudi in miši z izbitim genom za VCP niso viabilne, kar 
kaže, da ima ključno vlogo tako v enoceličnih kot v več celičnih organizmih (Müller et al. 
2007). Zelo pomembno funkcijo ima pri proteinski homeostazi, kjer omogoča proteasomsko 
degradacijo okvarjenih ali napačno zvitih proteinov. Veže se na proteine, označene z 
ubikvitinom, jih izloči od drugih ne ubikvitiniranih proteinov in jih dostavi do 
proteasomskega kompleksa (Ye, Meyer, and Rapoport 2001; Meyer and Weihl 2014; Ye et al. 
2017). Proteinu VCP so bile pripisane še številne druge vloge, kot je vpliv na nastanek 
stresnih granul pri odzivu na celični stres (Seguin et al. 2014) in spodbujanje njihove 
razgradnje (Buchan et al. 2013; B. Wang et al. 2019).  
Glede na pomembne in raznolike vloge proteina VCP v celičnih procesih, ne preseneča, da so 
mutacije v VCP povezane z več boleznimi, kot sta miopatija z inkluzijskimi telesci, Pagetova 
bolezen in frontotemporalna demenca (IBMPFD) (Watts et al. 2004) in ALS (Johnson et al. 
2010; Abramzon et al. 2012). Do danes je bilo identificiranih 45 mutacij v genu VCP (Saracino 
et al. 2018), ki povzročajo nastanek jedrnih in citoplazemskih agregatov proteina TDP-43 
(Forman et al. 2006; Neumann et al. 2007; Johnson et al. 2010; Ayaki et al. 2014). Mutacije v 
N-končni domeni VCP vodijo v zmanjšanje SUMOilacije, slabšo sestavo heksamera in 
pomanjkljiv odziv na stres (T. Wang et al. 2016). Študije fibroblastov so pokazale, da mutacije 
v VCP zmanjšajo mitohondrijski potencial (Bartolome et al. 2013).  
1.1.4. Ubiquilin-2 (UBQLN2) 
UBQLN2 je 66 kDa velik član družine ubikvilinov. Pri ljudeh poznamo štiri paraloge ubikvilina 
(1, 2, 3, in 4) in vsak izmed njih ima specifičen profil izražanja v tkivih (Renaud et al. 2019). 
Glavna funkcija proteina UBQLN2 je dostava ubikvitiniranih proteinov do proteaosma, 
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vključen pa je tudi v avtofagijo, celično signalizacijo, napredovanje celičnega cikla in 
citoskeletno asociacijo (Zhang et al. 2014). Vsebuje N-končno, ubikvitinu podobno domeno 
(UBL), ki interagira s podenotami proteasoma, C-končno z ubikvitinom-povezano domeno 
(UBA), ki interagira z ubikvitinom in poli-ubikvitinskimi verigami, ter štiri domene STI-1 v 
osrednji regiji proteina (Renaud et al. 2019). Protein UBQLN2 se od drugih članov družine 
ubikvilinov loči po edinstveni C-končni regiji, bogati s prolinom (PXX), ki vsebuje 12 
tandemskih ponovitev, vključenih v interakcije z drugimi proteini (Deng et al. 2011; Renaud 
et al. 2019).  
Leta 2011 so Deng in sodelavci poročali o petih mutacijah v genu za UBQLN2 (P497H, P497S, 
P506T, P509S in P525S), ki vodijo v dominantno obliko fALS povezano s kromosomom X. Vse 
mutacije se nahajajo v regiji PXX in vključujejo aminokislinske ostanke prolina (Deng et al. 
2011). Pozneje so pokazali, da ima vseh pet mutacij daljše razpolovne čase kot protein divjega 
tipa in da onemogočajo proteasomske aktivnosti ubikvilina-2 (Chang and Monteiro 2015). 
Poleg tega mutacije v ubikvilinu-2 spremenijo pogoje za njegovo fazno separacijo, vplivajo na 
njegovo topnost in spodbujajo oligomerizacijo (Kim et al. 2018; Dao et al. 2019). 
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1.2. Namen dela in hipotezi 
V zadnjih letih se vedno bolj uveljavlja prepričanje, da imajo citoplazemske inkluzije TDP-43 
lastnosti podobne prionskim proteinom (Nonaka and Hasegawa 2020). Za proteine z 
lastnostmi prionov je značilno sejanje novih agregatov v celicah z nativnimi proteini in 
njihovo širjenje med celicami. Novejše študije pa so pokazale, da agregati, izolirani iz 
prizadetih celic bolnikov z ALS in FTD, zavzamejo različne konformacije in imajo raznolike 
lastnosti, podobno kot velja za prionske seve (Furukawa et al. 2011; Nonaka et al. 2013; 
Smethurst et al. 2016; Porta et al. 2018; Laferrière et al. 2019). Alternativne konformacije 
patoloških agregatov bi lahko bile osnova za raznolikost proteinopatij TDP-43 in 
heterogenost poteka bolezni (Laferrière et al. 2019). Študije agregatov TDP-43 so pokazale 
nekatere razlike med inkluzijami bolnikov s FTD in mutacijami v genih za progranulin in 
C9orf72 (Takeda, Kitagawa, and Arai 2020). Kljub temu pa vloga genov, povezanih z ALS in 
njihovih mutacij na agregacijo TDP-43, ostaja neznanka. Zato smo v pričujoči študiji želeli 
primerjati vpliv več mutiranih in nemutiranih genov, povezanih z ALS, na agregacijo TDP-43 
in biokemijske lastnosti agregatov in vitro.  
Hipotezi, na katerih sloni raziskava, se osredotočata na dva vidika agregacije proteina TDP-
43. Na vpliv genov povezanih z ALS na agregacijo TDP-43: 
Izražanje z ALS povezanih genov (UBQLN2, MATR3, VCP, hnRNPA1) vpliva na 
biokemijske lastnosti in/ali celično lokalizacijo proteina TDP-43.  
Na citoplazemsko lokalizacijo agregatov TDP-43: 
Modeliranje okvar jedrno-citoplazemskega transporta v celicah zaostri patološke 
spremembe, ki so posledica izražanja posamezne mutacije povezane z ALS. 
Raziskovalno delo je bilo v večjem delu opravljeno na Inštitutu Jožefa Stefana, na Odseku za 
Biotehnologijo v Ljubljani. Del študije je bil opravljen na Ludwig Cancer Research v 
Laboratoriju Dona Clevelanda v San Diegu. Rezultati študije so bili objavljeni v naslednjem 
raziskovalnem članku: 
Bajc Česnik, A., Motaln, H., Rogelj, B. The Impact of ALS-Associated Genes hnRNPA1, MATR3, 
VCP and UBQLN2 on the Severity of TDP-43 Aggregation. Cells, 2020, 9(8). PMID: 32731393 
DOI: 10.3390/cells9081791  
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1.3. Metode 
1.3.1. Načrtovanje plazmidov in kloniranje 
Konstrukti TDP-43:  TDP-43 smo preklonirali iz objavljenega plazmida (Ling et al. 2010) v 
plazmid mKO2-C1, ki vsebuje zaporedje za fluorescenčni protein mKO2 (Addgene #54494). 
Nato smo zaporedje za mKO2-TDP-43 vstavili v plazmid pcDNA5/FRT/TO. Zaporedje NLS 
(82 a.k. to 98 a.k.) smo odstranili in vstavili kodone STOP za skrajšanje TDP-43 na C-končnem 
delu s pomočjo mestno-specifične mutageneze.   
Z ALS povezani geni: Najprej smo pomnožili fragment DNA, ki je vseboval zaporedje za 
mesto HRV 3C, povezovalec Gly-Ser-Gly in oznako 3xHA in ga vstavili v lineariziran plazmid 
pcDNA/FRT/TO. Nato smo pomnožili štiri z ALS povezane gene in jih vstavili v lineariziran 
plazmid pcDNA5/FRT/TOx3HA: VCP (Addgene #23971), UBQLN2 (Addgene #8661), 
hnRNPA1 (Addgene #23026), MATR3 (Addgene #32880). Z ALS-povezane mutacije smo 
vstavili s pomočjo mestno-specifične mutageneze.  
1.3.2. Celične kulture 
Celice celične linije SH-SY5Y smo gojili v eni plasti v mediju DMEM/F-12, z dodanim 10 % 
(v/v) FBS in raztopino P/S pri temperaturi 37 °C v vlažni atmosferi in 5 % CO2. Celice smo 
prehodno transfecirali s transfekcijskim reagentom Xfect. Da smo lahko rezultate primerjali 
med seboj, smo vse ko-transfekcije izvedli hkrati. 
1.3.3. Prenos western  
24 ur po transfekciji smo celice 3x sprali z ledeno hladnim PBS in jih lizirali v 2x nanašalnem 
pufru z SDS z dodanim 0.1 M DTT. Vzorce smo 10 min kuhali pri 100 °C in jih nato nanesli na 
8 - 16 % Tris-glicinske gele, ki so tekli v pufru SDS 90 min pri 120 V. Proteine smo prenesli 
na nitrocelulozno membrano. Membrano smo najprej enkrat sprali s TBS, nato blokirali 30 
min v 5 % posnetem mleku in inkubirali preko noči s primarnimi protitelesi, prav tako v 5 % 
posnetem mleku. Naslednji dan smo membrane 3x sprali s TBST in jih 1.5 h inkubirali s 
sekundarnimi protitelesi v 5 % posnetem mleku. Še 3x smo sprali s TBST in detektirali 
fluorescentni signal z napravo Chemidoc.  
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1.3.4. Imunocitokemija 
24 ur po transfekciji smo celice 3x sprali s PBS, jih 30 min fiksirali v 4 % PFA, spet sprali s 
PBS, 10 min permeabilizirali z 0.1 % TX-100, blokirali 30 min v 3 % BSA in preko noči 
inkubirali s protitelesi pri 4 °C. Naslednji dan smo objektna stekelca sprali, 2 h inkubirali s 
sekundarnimi protitelesi, 15 min inkubirali z raztopino DAPI in vklopili na mikroskopska 
stekla.  
1.3.5. Slikanje in statistična analiza 
Tri eksperimente smo izvedli v duplikatih za vsak eksperimentalni pogoj in za vsak duplikat 
smo posneli najmanj 15 vidnih polj, vsako s 50 - 70 celic. V celoti smo analizirali med 550 in 
3400 transfeciranih celic za vsak eksperimentalni pogoj. Odstotek transfeciranih celic z 
agregati TDP-43 smo kvantificirali z manualnim štetjem. Nadaljnjo analizo števila agregatov 
in njihove velikosti smo izvedli z vtičnikom ImageJ Shape Descriptors. 
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1.4. Rezultati 
Da bi preizkusili, kako C-terminalna domena vpliva na agregacijo TDP-43, smo celice SH-
SY5Y transfecirali z različnimi TDP-43 konstrukti, ki so bili označeni s fluorescenčnim 
proteinom mKO2, brez NLS (dNLS) in z odstranjenimi različnimi deli LCD (dNLSd343, 
dNLSd299 in dNLSd267) (glej sliko 1A). TDP-43 divjega tipa (TDPwt) smo uporabili kot 
kontrolo izhodiščnih vrednosti agregacije in samo fluorescenčni protein mKO2 (mKO2only) 
je služil za preizkus učinka fuzijskega proteina na agregacijo (slika 1A). Izražanje vseh 
konstruktov smo preverili s prenosom western in z detekcijo s protitelesom proti TDP-43 pri 
predvidenih velikostih (slika 1B). Po pričakovanjih je odstranitev NLS iz zaporedja za TDP-
43 vodila v povečanje citoplazemske agregacije konstrukta dNLS (24,4 ± 0,80 %) v primerjavi 
s TDPwt (3,8 ± 0,80 %) (slika 1C). Delecija IDR2 na skrajnem C-končnem delu TDP-43 
(dNLSd343) je vodila v še večji delež transfeciranih celic z agregati dNLS343 (33,0 ± 0,20 %). 
Dodatno krajšanje LCD je zmanjšalo delež celic z agregati dNLSd299 (6,9 ± 0,57 %) in 
dNLSd267 (4,1 ± 1,37 %). Nadaljnja analiza agregatov v vsaki posamezni celici je razkrila, da 
je izražanje dNLS vodilo do največjega povprečnega števila agregatov v citoplazmi (14,1 ± 
0,80) v primerjavi s katero koli drugo obliko skrajšanega TDP-43 (slika 1D). Največji agregati 
pa so bili v celicah, ki so izražale konstrukta dNLSd343 (4,2 ± 0,36 µm2) in dNLSd299 (4,8 ± 
0,61 µm2) (slika 1E in 1F).    
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Slika 1: Skrajšanje C-končne domene vpliva na nastanek agregatov TDP-43 v citoplazmi celic SH-SY5Y.  
(A) Shematski prikaz konstruktov označenih z mKO2 in njihove okrajšave. Samo TDPwt ima NLS, ostali 
konstrukti ga nimajo in vsi razen dNLS so skrajšani na C-koncu: dNLSd343 nima IDR2 (konča se pri 343 ak 
ostanku), dNLSd299 nima IDR2 in CR (konča se pri 299 ak ostanku), dNLSd267 nima celotne C-končne domene 
(konča se pri 267 ak ostanku). Kontrolni konstrukt KO2only vsebuje smo zaporedje za protein mKO2. (B) 
Analiza konstruktov označenih z mKO2 s prenosom western. (C) Kvantifikacija transfeciranih celic z agregati. 
(D) Povprečno število agregatov v posamezni celici. (E) Povprečna velikost agregatov v posamezni celici. (F) 
Celice SH-SY5Y, ki izražajo konstrukte, označene z mKO2. Jedra so obarvana z DAPI. Merilo: 10 µm. 
Ko-transfekcija tako dNLS kot dNLSd343 s hnRNPA1wt ali hnRNPA1mut je vodila v 
zmanjšanje deleža transfeciranih celic z agregati. Med deležem celic z agregati ko-
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transfeciranih z dNLS in hnRNPA1wt (10,5 ± 1,77 %) in hnRNPA1mut (14,7 ± 1,72 %) ni bilo 
razlike, ko-transfekcija dNLSd343 s hnRNPA1mut (14,6 ± 0,78 %) je vodila do višjega deleža 
celic s citoplazemskimi agregati v primerjavi s hnRNPA1wt (8,5 ± 1,02 %) (slika 2A). Poleg 
tega se je povprečno število agregatov v posamezni celici ko-transfecirani s hnRNPA1wt (4,9 
± 0,69) ali hnRNPA1mut (5,4 ± 0,80) in dNLS več kot prepolovilo v primerjavi s celicami ko-
transfeciranimi s kontrolnim plazmidom HAonly (13.1 ± 1.82) (slika 2B). Ko-transfekcija 
dNLS in dNLSd343 s hnRNPA1 je vodila v precejšnje zmanjšanje velikosti agregatov dNLS 
(0,7 ± 0,34 µm2) in dNLSd343 (1,2 ± 0,14 µm2) v primerjavi s celicami ko-transfeciranimi s 
kontrolnim plazmidom HAonly (dNLS (2,1 ± 0,34 µm2) in dNLSd343 (3,9 ± 0,39 µm2)) (slika 
2C in 2D). 
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Slika 2: Celice SH-SY5Y ko-transfecirane s konstrukti, označenimi z mKO2 in nativnim oziroma 
mutiranim hnRNPA1.  (A) Kvantifikacija ko-transfeciranih celic z agregati. (B) Povprečno število agregatov v 
posamezni celici. (C) Povprečna velikost agregatov. (D) Celice SH-SY5Y ko-transfecirane s konstrukti, 
označenimi z mKO2 in nativnim oziroma mutiranim hnRNPA1. Označene s protitelesom proti oznaki HA in 
obarvane z DAPI. Merilo: 10 µm. 
Ko-transfekcija dNLS ali dNLSd343 z MATR3wt ni imela učinka na odstotek celic z agregati 
dNLS (24,9 ± 1,34 %) ali dNLSd343 (26,5 ± 0,10 %). Po drugi strani pa je ko-transfekcija 
MATR3mut z dNLS ali dNLSd343 povečala delež celic z agregati dNLS (36,9 ± 0,75 %) in 
dNLSd343 (32,3 ± 1,02 %) (slika 3A). Niti MATR3wt niti MATR3mut nista imela učinka na 
število agregatov v posamezni celici (slika 3B), sta pa tako MATR3wt (5,1 ± 0,26 µm2) kot 
MATR3mut (3,7 ± 0,30 µm2) občutno povečala velikost agregatov v celicah ko-transfeciranih 
z dNLS (slika 3C in 3D). 
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Slika 3: Celice SH-SY5Y ko-transfecirane s konstrukti, označenimi z mKO2 in nativnim oziroma 
mutiranim MATR3.  (A) Kvantifikacija ko-transfeciranih celic z agregati. (B) Povprečno število agregatov v 
posamezni celici. (C) Povprečna velikost agregatov. (D) Celice SH-SY5Y ko-transfecirane s konstrukti, 
označenimi z mKO2 in nativnim oziroma mutiranim MATR3. Označene s protitelesom proti oznaki HA in 
obarvane z DAPI. Merilo: 10 µm. 
Ko-transfekcija dNLS ali dNLSd343 z VCPmut je povečala odstotek celic z agregati dNLS (39,7 
± 0,36 %) in dNLSd343 (32,3 ± 1,97 %) v primerjavi z deležem celic, ko-transfeciranih z 
VCPwt (dNLS (30,1 ± 1,04 %) in dNLSd343 (23,1 ± 0,95 %)) ali kontrolnim plazmidom 
HAonly (dNLS (27,0 ± 1,64 %) in dNLSd343 (26,5 ± 0,05 %)) (slika 4A). Vendar pa se je 
povprečno število agregatov dNLS v posamezni celici zmanjšalo tako pri celicah ko-
transfeciranih z VCPwt (7,4 ± 0,87) kot z VCPmut (6,4 ± 1,35) v primerjavi s celicami ko-
transfeciranimi s kontrolnim plazmidom HAonly (13,1 ± 1,82) (slika 4B). Povprečna velikost 
teh agregatov se je povečala tako pri celicah ko-transfeciranih z VCPwt (4,2 ± 0,25 µm2) kot 
z VCPmut (4,2 ± 0,24 µm2) v primerjavi s HAonly (2,1 ± 0,34 µm2) (slika 4C in D). 
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Slika 4: Celice SH-SY5Y ko-transfecirane s konstrukti, označenimi z mKO2 in nativnim oziroma 
mutiranim VCP.  (A) Kvantifikacija ko-transfeciranih celic z agregati. (B) Povprečno število agregatov v 
posamezni celici. (C) Povprečna velikost agregatov. (D) Celice SH-SY5Y ko-transfecirane s konstrukti, 
označenimi z mKO2 in nativnim oziroma mutiranim VCP. Označene s protitelesom proti oznaki HA in obarvane 
z DAPI. Merilo: 10 µm. 
Podobno kot pri VCPmut je ko-transfekcija konstrukta dNLS z UBQLN2mut (39,0 ± 0,83 %) 
vodila do povečanja deleža celic z agregati v primerjavi s HAonly (27,0 ± 1,64 %) ali 
UBQLN2wt (27,0 ± 0,92 %) (slika 5A). Nasprotno pa je ko-transfekcija dNLSd343 z 
UBQLN2wt (21,5 ± 1,21 %) vodila v zmanjšanje deleža celic z agregati v primerjavi s celicami 
ko-transfeciranimi s HAonly (26,5 ± 0,05 %) ali UBQLN2mut (28,1 ± 0,07 %). Za UBQLN2 se 
zdi, da ima vpliv na nastanek agregatov dNLS, saj je ko-transfekcija dNLS in UBQLN2wt (6,9 
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± 0,70) zelo zmanjšala število dNLS agregatov v posamezni celici (slika 5B), kar pa ni imelo 
učinka na njihovo velikost ali znotrajcelično distribucijo (slika 5C in D). 
 
 
Slika 5: Celice SH-SY5Y ko-transfecirane s konstrukti, označenimi z mKO2 in nativnim oziroma 
mutiranim UBQLN2.  (A) Kvantifikacija ko-transfeciranih celic z agregati. (B) Povprečno število agregatov v 
posamezni celici. (C) Povprečna velikost agregatov. (D) Celice SH-SY5Y ko-transfecirane s konstrukti, 
označenimi z mKO2 in nativnim oziroma mutiranim UBQLN2. Označene s protitelesom proti oznaki HA in 
obarvane z DAPI. Merilo: 10 µm. 
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1.5. Razprava 
Kljub temu, da so za veliko večino primerov ALS značilni citoplazemski skupki proteina TDP-
43 v prizadetih celicah, je med posameznimi bolniki ALS velika fenotipska raznolikost 
(Takeda, Kitagawa, and Arai 2020). Patološka in klinična heterogenost bi lahko vsaj deloma 
izvirala iz različnih strukturnih konformacij proteina TDP-43 (Jaunmuktane and Brandner 
2019). Pokazali so že, da imajo inkluzije TDP-43, pridobljene iz možganov bolnikov s FTLD, 
različno gostoto, morfologijo, nevro-toksičnost in zmožnost sejanja. Vse te lastnosti so bile 
povezane z dolžino trajanja bolezni in njenim podtipom (Laferrière et al. 2019). Navkljub 
naštetim raziskavam, pa manjkajo študije, ki bi pokazale, kako z ALS-povezani geni vplivajo 
na obnašanje agregatov TDP-43 in s tem na heterogenost bolezni.  
Z našo študijo smo želeli raziskati vpliv genov in njihovih mutacij, povezanih z ALS na 
lokalizacijo, biokemijske lastnosti in agregacijo TDP-43 v modelu okvarjenega jedrno-
citoplazemskega transporta. Okvarjeni jedrno-citoplazemski transport smo modelirali tako, 
da smo iz celotnega zaporedja za TDP-43 odstranili NLS. Ker fiziološka oligomerizacija TDP-
43 preko N-končne domene prostorsko loči domene LCD (Afroz et al. 2017), smo nativno 
konformacijo oligomerov TDP-43 poskušali zmotiti s skrajšanjem C-končnega zaporedja. 
Fragmente TDP-43 smo načrtali po mejah, ki so jih določili Schmidt in sodelavci (Schmidt, 
Barreau, and Rohatgi 2019). Tako kot drugi (Ishii et al. 2017; Zhang et al. 2013) smo tudi mi 
pokazali, da izražanje celotnega TDP-43 divjega tipa le redko vodi do nastanka agregatov. V 
skladu z literaturo (Zhang et al. 2013) smo pokazali tudi, da izražanje dNLS vodi do številnih 
drobnih agregatov v približno četrtini transfeciranih celic. Kljub nižjim ravnem izražanja je 
približno tretjina celic, transfeciranih z dNLSd343, vsebovala sicer malo-številne, vendar 
večje in obsežnejše agregate kot dNLS. To opažanje nakazuje, da odstranitev IDR2 iz 
zaporedja za TDP-43 spremeni nagnjenost dNLSd343 za LLPS in nastanek agregatov ter 
usmeri proces v povečevanje agregatov v velike netopne inkluzije. Odstranitev CR iz 
dNLSd299, ni popolnoma preprečila nastanka agregatov, saj je približno 7 % celic še vedno 
vsebovalo malo-številne, velike inkluzije. Po drugi strani smo z delecijo celotnega LCD iz 
dNLSd267 dosegli enake ravni nastanka agregatov kot v kontrolnih celicah.  
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Izražanje dNLS in dNLS343 v celični liniji SH-SY5Y je tako vodilo do dveh različnih vzorcev 
agregacije: dNLS je tvoril številne majhne razpršene agregate, dNLSd343 pa bolj redke a večje 
in obsežnejše agregate. Zato smo se odločili, da bomo nadalje raziskali vpliv štirih izbranih z 
ALS-povezanih genov in njihovih mutacij v obeh modelih agregacije TDP-43.  
hnRNPA1 je član družine proteinov hnRNP, ki so vključeni v izrezovanje intronov, 
stabilizacijo mRNA, biogenezo miRNA in regulacijo transkripcije (Bekenstein and Soreq 
2013; Roy et al. 2017; Howard et al. 2018; Kattuah et al. 2019). Ko-transfekcija tako 
hnRNPA1wt kot mut z dNLS ali dNLSd343 je vodila v zmanjšanje števila celic z agregati dNLS 
oziroma dNLSd343. Ko-ekspresija dNLS in dNLSd343 s hnRNPA1 je v celicah povzročila 
zmanjšanje števila agregatov, ki so bili majhni in bolj okrogli, kar nakazuje da se lahko 
proteini v gosti fazi dinamično izmenjujejo z okoliškimi proteini v bolj razredčeni fazi. 
hnRNPA1 lahko tvori reverzibilne amiloidne fibrile, ki so v dinamičnem stanju proteinskih 
skupkov z visokimi prostimi energijami (Gui et al. 2019). Skupaj z dejstvom, da C-končni del 
TDP-43 neposredno interagira s C-končnim delom hnRNPA1 (Buratti et al. 2005) in da skupaj 
prehajata fazno separacijo (Gasset-Rosa et al. 2019), lahko predvidevamo, da njune 
interakcije spodbujajo bolj homogeno raztapljanje proteinov z manj gostimi dinamičnimi 
strukturami. Poleg tega je nedavna študija agregatov TDP-43 z mikroskopijo na atomsko silo 
pokazala, da fragmenti TDP-43 brez C-končne domene oblikujejo manjše agregate kot 
protein celotne dolžine (French et al. 2019). To se sklada z idejo, da medmolekulske 
interakcije med TDP-43 in hnRNPA1 preko nujnih C-končnih domen prostorsko ločijo 
domene LCD, ki so nagnjene k agregaciji in zmanjšajo število večjih agregatov, kar smo opazili 
v naši študiji. Kljub temu, da ima hnRNPA1 tendenco za LLPS in lahko tvori ireverzibilne 
fibrile (Kim et al. 2013; Molliex et al. 2015; Lin et al. 2015) nismo z mikroskopsko analizo 
zaznali nobenih citoplazemskih akumulacij hnRNPA1wt oziroma hnRNPA1mut. Smo pa 
zaznali razliko med številom celic z agregati, ki so bile ko-transfecirane z dNLSd343 in 
hnRNPA1wt ali mut, kar nakazuje na promocijski učinek mutacije D262V na LLPS dNLSd343 
proti nastanku agregatov. 
Tudi MATR3 je RNA-vezavni protein. Nahaja se v jedrnem matriksu in je vključen v številne 
naloge, povezane z nukleinskimi kislinami, kot so organizacija kromatina, podvojevanje, 
prepisovanje in popravilo DNA, procesiranje ter prenos, stabilizacija in alternativno 
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izrezovanje RNA (Salton et al. 2010; 2011; Coelho et al. 2015; Attig et al. 2018; Zhao et al. 
2018). Ko-transfekcija MATR3 z mutacijo S85C in TDP-43 dNLS oziroma dNLSd343 je 
povečala število celic z agregati v primerjavi z MATR3wt oziroma kontrolnim plazmidom. 
Nižje ravni RNA spodbujajo LLPS RNA-vezavnih proteinov (Maharana et al. 2018) in skupki 
TDP-43 brez RNA so netopni (Mann et al. 2019; Gasset-Rosa et al. 2019). Izražanje MATR3 z 
mutacijo S85C zadržuje mRNA v jedru (Boehringer et al. 2017), kar morda povzroči, da dNLS 
in dNLSd343 lažje preideta fazno separacijo, kar nagne ravnotežje proti netopnim inkluzijam. 
Tudi N-končno zaporedje MATR3 izkazuje nizko kompleksnost in je podvrženo fazni 
separaciji tako da tvori tekočini-podobne kapljice v jedru (Iradi et al. 2018; Gallego-Iradi et 
al. 2019). Mutacija S85C MATR3 inhibira nastanek kapljic (Malik et al. 2018; Gallego-Iradi et 
al. 2019), kar morda razloži povečanje agregatov dNLS, sploh v ko-transfekciji z MATR3wt.   
Ena izmed nalog proteina VCP je omogočanje proteasomske degradacije poškodovanih in 
napačno zvitih proteinov (Ye, Meyer, and Rapoport 2001; Meyer and Weihl 2014; Ye et al. 
2017). Topni TDP-43 primarno razgrajuje ubikvitinsko-proteasomski sistem, medtem ko se 
agregati TDP-43 odstranjujejo z avtofagijo (Scotter et al. 2014).  Zato ni presenetljivo, da ko-
ekspresija VCPmut s TDP-43 dNLS in dNLSd343 poveča delež transfeciranih celic z agregati 
dNLS in dNLSd343. Povečano število agregatov bi lahko bila posledica okvarjenega proteina 
VCP, ki se neuspešno vključuje v procese degradacije TDP-43. Vendar pa ko-ekspresija VCPwt 
s TDP-43 dNLS oziroma dNLSd343 ne zmanjša odstotka transfeciranih celic z agregati, 
čeprav naj bi bil VCP zmožen preprečiti nastanek agregatov (Song, Wang, and Li 2007), kar 
nakazuje na zgornjo omejitev proteolitičnih procesov pri razgradnji nepravilno zvitih 
proteinov. VCP ima poleg razgradnje proteinov vlogo tudi pri drugih celičnih nalogah, kot je 
vključenost v odgovor na celični stres, kjer vpliva na nastanek stresnih granul (Seguin et al. 
2014) in na njihovo odstranitev (Buchan et al. 2013; Wang et al. 2019). Stresne granule 
nastanejo preko LLPS (Dobra et al. 2018) in so RNA-proteinski agregati, ki vsebujejo TDP-43 
in druge z ALS-povezane proteine (Colombrita et al. 2009; Liu-Yesucevitz et al. 2010; Dewey 
et al. 2011; McDonald et al. 2011; Vance et al. 2013), za katere velja, da so prekurzorji 
patoloških citoplazemskih inkluzij (Dewey et al. 2012), podobnim agregatom, ki so 
modelirani z našimi konstrukti. Tako bi lahko vloga VCP pri odstranjevanju stresnih granul 
razložila njegov inhibitorni učinek na velikost in netopnost agregatov dNLS v primerjavi s 
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kontrolo. Pravkar objavljeni podatki kažejo, da v stanju hiperosmotskega stresa VCP skupaj 
z drugimi proteini, ki interagirajo s proteasomi tvori jedrne proteasomske fokuse z 
lastnostmi tekočih kapljic (Yasuda et al. 2020). V luči te študije je mogoče, da VCP aktivno 
vpliva na pogoje za LLPS dNLS in  s tem spremeni njihove lastnosti. 
Kot VCP tudi UBQLN2 sodeluje pri procesih proteolize, kot je dostava ubikvitiniranih 
proteinov do proteasoma (Zhang et al. 2014). Vključen pa je tudi v avtofagijo, celično 
signaliziranje, napredovanje celičnega cikla in povezovanje s citoskeletom (Zhang et al. 
2014). Podobno kot pri VCP, tudi ko-transfekcija celic z UBQLN2 z mutacijo P506T s TDP-43 
dNLS, povzroči povečan odstotek transfeciranih celic z agregati v primerjavi s kontrolo 
oziroma UBQLN2wt. Verjetno vzrok prav tako leži v interakciji mutiranega UBQLN2 z 
degradacijskimi potmi TDP-43. V nasprotju z VCP pa ko-ekspresija TDP-43 dNLSd343 z 
UBQLN2wt zmanjša delež transfeciranih celic z agregati, kar kaže na zmožnost UBQLN2wt, 
da pospeši razgradnjo dNLSd343. Tudi UBQLN2 je povezan s komponentami stresnih granul 
in regulira njihov nastanek z zadrževanjem iniciacijskih procesov (Alexander et al. 2018). To 
bi lahko razložilo zmanjšanje števila agregatov pri celicah ko-transfeciranih z UBQLN2wt in 
dNLS. Poleg tega pa je tudi sam UBQLN2 podvržen LLPS (Dao et al. 2018) in njegove mutacije, 
povezane z ALS, spremenijo njegove lastnosti za LLPS, vplivajo na njegovo topnost in 
spodbujajo oligomerizacijo (Dao et al. 2019). To se sklada z opaženim povečanim deležem 
celic z agregati po ko-transfekciji z UBQLN2mut in dNLS. Zaznali smo tudi ko-lokalizacijo 
UBQLN2 z agregati dNLS, kar nakazuje na mogoč recipročen vpliv na njuno nagnjenost za 
fazno separacijo. UBQLN2mut ni vplival na vzorec agregacije dNLSd343, kar lahko nakazuje, 
da so lahko manjkajoči aminokislinski ostanki ključni za interakcijo TDP-43 in UBQLN2 med 
fazno separacijo in začetnih stopnjah nastanka agregatov.  
V zadnjih letih postajata heterogenost ALS in njeno klinično, patološko in genetsko 
prekrivanje z drugimi nevrodegenerativnimi boleznimi vedno bolj očitna (Taylor, Brown, 
and Cleveland 2016). Vseeno pa se študije še vedno osredotočajo na posamezne gene in 
procese ter zanemarjajo potrebo po povezovanju patoloških poti z nastankom in 
napredovanjem bolezni. Naša študija je pokazala, da vsak izmed raziskovanih genov, 
povezanih z ALS, edinstveno vpliva na agregacijo TDP-43, kar kaže na pomembnost njihovih 
poti za napredovanje in resnost bolezni. Lahko bi celo trdili, da vsak od raziskovanih genov v 
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ko-transfekciji z agregirajočim konstruktom vodi do nastanka specifičnega »tipa agregatov,« 
podobno kot so jih identificirali Laferrière in sodelavci (Laferrière et al. 2019), kar bi lahko 
predstavljalo temelj za heterogenost bolezni.  
Vendar pa je določitev vpliva z ALS-povezanih genov na vzorce agregacije TDP-43 samo prvi 
korak pri razkrivanju mehanizma nastanka agregatov TDP-43. Razlike med vzorci agregacije 
TDP-43 bi bilo potrebno potrditi tudi pri agregatih, pridobljeni iz tkiv post mortem ali 
motoričnih nevronov, izpeljanih iz pacientov z različnimi mutacijami v genih, povezanimi z 
ALS. Potrebne so tudi dodatne študije, ki bi razkrile učinke interaktorjev TDP-43 s 
potencialom za povečanje ali zmanjšanje agregacije TDP-43 v povezavi z mutacijami v z ALS-
povezanimi geni.  
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1.6. Sklepi 
S pričujočo študijo smo v kontekstu okvarjenega jedrno-citoplazemskega transporta želeli 
raziskati vpliv, ki ga imajo z ALS-povezani geni na lokalizacijo in biokemijske lastnosti 
proteina TDP-43. Uspešno smo potrdili obe zastavljeni hipotezi. 
Izražanje z ALS povezanih genov (UBQLN2, MATR3, VCP, hnRNPA1) vpliva na 
biokemijske lastnosti in/ali celično lokalizacijo proteina TDP-43.  
In 
Modeliranje okvar jedrno-citoplazemskega transporta v celicah zaostri patološke 
spremembe, ki so posledica izražanja posamezne ALS mutacije. 
Okvaro jedrno-citoplazemskega transporta smo modelirali z odstranitvijo NLS iz zaporedja 
za protein TDP-43, kar je vodilo do citoplazemskih agregatov konstrukta TDPdNLS. Približno 
četrtina transfeciranih celic SH-SY5Y je vsebovala številne drobne agregate. Pokazali smo, da 
dodatno krajšanje domene LCD vodi do različnih vzorcev agregacije TDP-43. Najbolj nas je 
presenetil konstrukt TDP-43dNLSd343, ki je v približno tretjini transfeciranih celic povzročil 
nastanek sicer ne tako številnih, zato pa toliko večjih agregatov v primerjavi s konstruktom 
dNLS. Potrdili smo, da je konstrukt dNLSd343 kljub odstranjenim aminokislinskim ostankom 
na ekstremnem C-končnem delu domene LCD zadržal zmožnost privzemanja nativnega 
proteina TDP-43 v agregate. Vseeno pa nam z eksperimenti rasti celic v ko-kulturi in z 
dodajanjem supernatanta odvzetega s celic z agregati ni uspelo povzročiti vsesplošnega 
razširjanja agregacije v prejemniških celicah. Predpostavljamo, da membranska ovojnica 
okoli agregatov preprečuje stik s proteini divjega tipa v prejemniških celicah. 
Ker sta oba konstrukta dNLS in dNLSd343 povzročila edinstven in izrazit vzorec agregacije, 
smo se odločili, da bomo za študijo vpliva z ALS-povezanih genov na lokalizacijo in 
biokemijske lastnosti TDP-43 uporabili oba. 
S ko-transfekcijo konstruktov dNLS in dNLSd343 z mutiranimi in nemutiranimi z ALS-
povezanimi geni smo pokazali, da ima vsak izmed testiranih genov edinstven vpliv na 
vzorec agregacije TDP-43, kar spremeni njegovo lokalizacijo in potrdi drugi del prve 
hipoteze in na topnost agregatov, kar spremeni njegove biokemiske lastnosti in potrdi prvi 
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del prve hipoteze. Te učinke smo preučevali v kontekstu okvarjenega 
nukleocitoplazemskega transporta, ki je zaostril patološko agregacijo v celicah ko-
transfeciranih z mutiranimi ali nemutiranimi z ALS-povezanimi geni, s čimer smo potrdili 
drugo hipotezo. Nekateri geni, kot sta na primer mutirani in nemutirani hnRNPA1 so 
zmanjšali število agregatov in povečali njihovo topnost, drugi pa so povečali število agregatov 
in/ali njihovo velikost in/ali zmanjšali njihovo topnost. Pokazali smo tudi, da vsak izmed 
genov edinstveno vpliva tako na dNLS kot na dNLSd343, kar kaže na pomembno vlogo 
skrajnega C-končnega dela domene LCD pri nastanku in maturaciji agregatov. Izsledki naše 
študije tako potrjujejo, da vsak izmed z ALS-povezanih genov, ki smo jih raziskovali, 
edinstveno vpliva na procese agregacije TDP-43, kar vodi do nastanka različnih »tipov 
agregatov,« ki bi lahko predstavljali temelj za heterogenost bolezni ALS. 
Naša študija, predstavljena v tej doktorski disertaciji je prva, ki primerja vpliv z ALS-
povezanih genov na agregacijo proteina TDP-43. V sklopu študije smo tudi razvili model 
agregacije proteina TDP-43, s katerim bi lahko v prihodnosti raziskovali zmožnost 
potencialnih terapevtskih učinkovin za zmanjšanje ali eliminacijo agregatov TDP-43 in s tem 
izboljšanje patoloških sprememb v prizadetih celicah bolnikov z ALS. Naši rezultati potrjujejo 
potrebo po primerjalnih raziskavah na področju ALS in razkrivajo, kako različni mehanizmi 
interagirajo na molekulskem nivoju in vodijo v nevrodegeneracijo, kar se bo morda izkazalo 
kot ključnega pomena za uspešen razvoj terapevtikov. 
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2. Literature Review 
2.1. Amyotrophic Lateral Sclerosis 
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease with a 
signature pathology of dying lower motor neurons (LMN) and upper motor neurons (UMN) 
in the brain and in the spinal cord. Jean-Martin Charcot first described it in 1874 and coined 
the term amyotrophic lateral sclerosis. The phrase “lateral sclerosis” refers to the changes in 
morphology in the lateral spinal cord, where motor neuron tracts degenerate and appear 
scarred and the term “amyotrophic” describes the consequent loss of muscle mass. Later, 
other names for the disease became predominant in different parts of the world – Lou 
Gehrig’s disease in the United States and motor neuron disease in the United Kingdom 
(Taylor, Brown, and Cleveland 2016; Takeda, Kitagawa, and Arai 2020).  
The average age of onset is raging between 54 to 67 years old; however, ALS can present 
itself at almost every stage of life, with the exception of the early childhood. Between 5 - 10 
% of the cases are familial, others are of unknown etiology. 1 - 2.6 individuals per 100.00 are 
diagnosed each year, with the prevalence of 5 patients per 100.000 people, reflecting its’ 
rapid progression (Taylor, Brown, and Cleveland 2016; Connolly et al. 2020). Incidence ratios 
between males and females is ranging from 1.3 to 1.5 (Brotman et al. 2020). The symptoms 
include cramping and weakness; they usually start at a focal point and then spread to the 
neighboring regions, resulting in the paralysis of almost all skeletal muscles. Death typically 
occurs 3-5 years after the diagnosis, usually, due to the respiratory arrest, although some 
patients display longer survival (Taylor, Brown, and Cleveland 2016).     
2.2. Clinical Features of ALS 
ALS is a very heterogeneous disorder with many different clinical manifestations, 
distinguished by the different motor neuron involvement, location of the onset and most 
affected body parts (Gordon 2013; Swinnen and Robberecht 2014; Taylor, Brown, and 
Cleveland 2016; Brotman et al. 2020). UMN signs and symptoms include hyperreflexia and 
spasticity, while LMN signs and symptoms include muscle atrophy and fasciculations. 
Weakness can be a sign of either UMN or LMN involvement (Brotman et al. 2020). Currently, 
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the diagnosis is based on a set of clinical criteria that can be used to stratify patients according 
to the area of initial onset and the progression of symptoms (Connolly et al. 2020). ALS 
phenotypes include classic ALS, progressive muscular atrophy, primary lateral sclerosis, 
pseudopolyneuritic ALS, hemiplegic ALS, flail arm syndrome and flail leg syndrome (Figure 
1) (Swinnen and Robberecht 2014). The most common is classic ALS with three different 
sites of onset – spinal, bulbar and respiratory.  
 
Figure 1: Signature motor involvement in different ALS phenotypes.  Red indicates LMN involvement, blue 
indicates UMN and darker shading indicates more severe involvement (Swinnen and Robberecht 2014) (with 
permission from Nature Publishing Group).  
2.2.1. Spinal-Onset 
Spinal-onset is the most common ALS phenotype, affecting approximately 70 % of cases, 
usually occurring around the age of 60. The symptoms include atrophy, muscle weakness and 
fasciculations, which indicate the lower motor neuron involvement, and hyperreflexia and 
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mild to severe hypertonia, indicating the upper motor neuron involvement. At the beginning, 
the symptoms might be restricted to certain body areas, however, they contiguously progress 
over time, suggesting a spread of the pathology at a cellular level (Ravits and La Spada 2009; 
Swinnen and Robberecht 2014; Connolly et al. 2020).   
2.2.2. Bulbar-Onset 
Around 20 - 25 % of the ALS patients initially present the symptoms in the bulbar regions, 
displaying dysarthria, dysphagia and tongue fasciculations. Bulbar-onset is more common in 
female patients, especially for those over 70 years of age. The symptom progression is usually 
gradual, but for some of the patients the disease appears so suddenly that stroke and 
myasthenia are considered in the differential diagnosis. The prognosis for the patients with 
the bulbar-onset ALS is worse than for the patients with the spinal-onset, with the mean 
survival of 2 years, possibly due to the eating and respiration difficulties (Swinnen and 
Robberecht 2014; Connolly et al. 2020).   
2.2.3. Respiratory-Onset 
A small proportion of ALS patients (3 - 5 %) present with respiratory or cognitive onset, 
characterized as truncal weakness or respiratory impairment, but small or absent bulbar or 
spinal signs. The prognosis for these patients is extremely poor, with a mean survival of 1.4 
years (Swinnen and Robberecht 2014). 
2.2.4. Overlap with Frontotemporal Dementia 
Frontotemporal dementia (FTD) is a group of disorders, characterized by the loss of neurons 
in frontal and temporal lobes, with diverse clinical, pathological and genetic signature, 
presenting as changes in personality, behavioral disturbances and impaired judgement. It is 
the second most common cause of dementia among younger people, after Alzheimer’s 
disease, with a prevalence up to 4 - 22 in 10.000 in those aged between 45 and 65 years 
(Mann and Snowden 2017; Ji et al. 2017). For decades, ALS and FTD were thought to be two 
separate conditions, due to their distinct clinical phenotypes. However, approximately 20 % 
of ALS patients are diagnosed with FTD and about 50 % of the ALS patients experience 
cognitive decline (Ferrari et al. 2011; Taylor, Brown, and Cleveland 2016). In the recent years, 
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ALS and FTD are thought to be a part of one continuum, with pure ALS cases and pure FTD 
cases representing opposite ends of the spectrum (Connolly et al. 2020). The link between 
these two disorders is also supported by numerous overlapping genes, leading to both 
pathological conditions (Ferrari et al. 2011).  
2.3. Genetic risks for ALS and FTD 
Most of the breakthroughs in ALS research are associated with the identification of novel ALS 
pathogenic variants and the characterization of the respective genes. However, many of the 
isolated genes are poorly characterized, and relatively little is known about their in vivo 
function. About 10 % of the ALS cases are of familial origin, they are usually transmitted as 
an autosomal dominant mutation and often with a high penetrance (Taylor, Brown, and 
Cleveland 2016). The first identified ALS causing gene was SOD1, coding for superoxide 
dismutase 1 protein (Rosen et al. 1993). Since then, more than 50 ALS genes have been 
published (Taylor, Brown, and Cleveland 2016), implicated in four major pathways 
contributing to the pathogenesis of disease: 
 disruption of RNA metabolism and translational biology (C9ORF72, TARDBP, FUS, 
TIA1, MATR3, HNRNPA1, HNRNPA2/B1, EWSR1, TAF15, ANG); 
 aberrant regulation of protein quality control (UBQLN2, VCP, OPTN, VAPB, TBK1, 
SQSTM1); 
 cytoskeletal defects and trafficking abnormalities (PFN1, TUBA4A, KIF5A, ANXA11); 
 and mitochondrial dysfunction (SOD1, CHCHD10) (Cook and Petrucelli 2019). 
A significant number of ALS cases are thought to be caused by mutations in multiple genes 
(Blitterswijk et al. 2012). Genome-wide association studies have shown that around 100 
genetic loci are linked to ALS with a low penetrance and a small contribution for each gene 
(Figure 2). Delineating the genetic interactions between different disease-causing genes 
allows elucidation of the pathogenic mechanisms. However, most of these genes still need to 
be validated and until then, their role in ALS pathogenesis will be uncertain (Ji et al. 2017). In 
the next chapters, we will take a closer look at the first identified ALS-associated gene SOD1, 
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and then TDP-43, hnRNPA1, MATR3, VCP and UBQLN2, which are the focus of this research 
study. 
 
Figure 2: Genetic contribution to ALS and FTD. The ALS and FTD phenotypes are presented along Y- and X-
axis, from the low penetrance polygenic causes at the beginning, to the high penetrance monogenic causes at 
the end of both axes. The relative contribution of each gene to the overall pathology is represented by their size 
and the contribution to each phenotype by the position along the axis (Ji et al. 2017) (with permission from BMJ 
Publishing Group Ltd.).  
2.3.1. SOD1 
SOD1 is a 33 kDa homodimeric antioxidant enzyme containing two Cu/Zn sites, each holding 
a copper and a zinc ion with the task of preventing cellular damage inflicted by reactive 
oxygen species (Wright, Antonyuk, and Hasnain 2019). It is ubiquitously expressed and 
makes up 1 - 2 % of the total soluble protein in the central nervous system (Bunton-Stasyshyn 
et al. 2015).  Autosomal dominant SOD1 mutations account for around 13 % of familial and a 
small percentage (1 %) of sporadic ALS. To this date, more than 180 ALS causing 
polymorphisms have been identified within the SOD1 gene and they are distributed 
throughout the 153 amino acids of the protein (Wright, Antonyuk, and Hasnain 2019). Most 
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mutations lower the catalytic activity of the enzyme, however, mouse models argue against 
loss of function as a cause of the pathology (Bruijn et al. 1998). As mutations in the SOD1 
increase the propensity of the protein to misfold and assemble into insoluble aggregates, the 
gain of function mechanisms are thought to be responsible for the disease onset and 
progression (Bruijn et al. 1998; Ji et al. 2017). Patients display a wide distribution of 
longevities following the onset of symptoms indicating that a necessary load of toxic SOD1 
species must be met before cell death ensues (Wright, Antonyuk, and Hasnain 2019). 
2.3.2. TDP-43 
In the year of 2006, the ALS research community was astounded by the revelation of Lee-
Trojanowski group, that the main component of cytoplasmic inclusions in the affected 
neurons of ALS and FTLD patients, was protein TDP-43 (Neumann et al. 2006). The protein 
aggregates were phosphorylated, ubiquitinated and cleaved into 25 kDa C-terminal 
fragments (Neumann et al. 2006). Two years later, a group of researchers led by Chris Shaw 
were the first to show that mutations in C-terminal region of TARDBP gene can lead to ALS 
pathology (Sreedharan et al. 2008) and since then more than 50 ALS-causing missense 
mutations have been identified in TDP-43 (Figure 3), accounting for 1 - 2 % of total ALS cases 
(Kapeli, Martinez, and Yeo 2017). 
 
Figure 3: ALS-causing mutations along TDP-43 protein. 
TDP-43 was first identified as a transcription factor binding to the TAR regulatory element 
in HIV-1 long terminal repeat. The protein migrated on the gel around the size of 43 kDa and 
consequently got the name TDP-43 (TAR DNA-binding Protein-43) (Ou et al. 1995). Since 
then, involvement in different steps of RNA processing, such as splicing, mRNA stability, 
stress granule formation and miRNA biogenesis has been thought to be among primary roles 
of TDP-43 (Buratti and Baralle 2008; Harrison and Shorter 2017; Loughlin and Wilce 2019).    
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TDP-43 is a 414 amino acid long, ubiquitously expressed, predominantly nuclear protein 
belonging to the heterogeneous ribonucleoprotein (hnRNP) family (Buratti and Baralle 
2008). It consists of two RNA recognition motifs (RRM1 and RRM2), nuclear import (NLS) 
and export (NES) signals, C-terminal glycine-rich region, which has properties of a low-
complexity domain (LCD) and is supposedly involved in protein-protein interactions, and N-
terminal domain, mediating TDP-43 oligomerization (Figure 3) (Buratti and Baralle 2008; 
Afroz et al. 2017; Loughlin and Wilce 2019). Although most of the TDP-43 protein is localized 
in the nucleus, NLS and NES allow it to shuttle to the cytoplasm and back (Winton et al. 2008). 
TDP-43 tightly regulates its own transcription by binding to a highly conserved 3’ untraslated 
region (UTR) and promoting degradation of the TARDBP transcript (Ayala et al. 2011).  
In addition to interactions with other proteins, LCD of TDP-43 is crucial for its liquid-liquid 
phase separation (LLPS), a process leading to formation of membraneless organelles such as 
stress granules (Conicella et al. 2016; Schmidt, Barreau, and Rohatgi 2019). LLPS has also 
been implicated as a possible inception mechanism for protein aggregation and subsequent 
self-templating, ultimately resulting in various types of irreversible inclusions i.e. amyloid-
like fibrils in neurodegenerative disease (Babinchak and Surewicz 2020). LCD of TDP-43 can 
be divided into three segments: two intrinsically disordered regions (IDR1 and IDR2) 
interspaced with a conserved region (CR) prone to adapt α-helical fold (Figure 3) (Schmidt, 
Barreau, and Rohatgi 2019). Hydrophobic intermolecular interactions between α-helical 
regions of TDP-43 are thought to drive its LLPS (Conicella et al. 2016; Li et al. 2018; Schmidt, 
Barreau, and Rohatgi 2019). The role of N-terminal domain in TDP-43 aggregation is 
somewhat controversial: while some argue that oligomerization of TDP-43 via its N-terminal 
domain allows interactions with other partner proteins and RNA, thereby antagonizing its 
pathological aggregation, others suggest that it enhances the propensity of the intrinsically 
disordered C-terminal region towards aggregation (Afroz et al. 2017; Tsoi et al. 2017). It has 
been shown that disruption of the N-terminal domain reduces propensity of TDP-43 to 
undergo LLPS and to form aggregates (Zhang et al. 2013; A. Wang et al. 2018). Moreover, 
TDP-43 contains two highly conserved RRMs, capable of binding to single strand RNA or DNA, 
which in turn enhances its solubility and prevents its aggregation (Huang et al. 2013; Sun et 
al. 2014; Solomon et al. 2018; Mann et al. 2019; French et al. 2019). 
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To date, many different post-translational modifications associated with TDP-43 have been 
detected in ALS/FTD patients; the most prevalent are phosphorylation, generation of C-
terminal domain fragments, ubiquitination, acetylation, cysteine oxidation and sumoylation 
(Buratti 2018). All of these modifications have a potential to alter functional properties, 
localization and aggregation tendencies of TDP-43. 
About 97 % of all ALS and 45 % of all FTD patients harbor TDP-43 positive cytoplasmic 
inclusions in the affected neurons and glial cells (Lim et al. 2016). However, in the 
overwhelming majority of cases, the accumulation is not associated with TDP-43 mutation 
(Taylor, Brown, and Cleveland 2016). The exact mechanisms driving TDP-43 deposition into 
the aggregates are unknown; however, extensive research has proposed several hypotheses 
for the disease onset and progression. As most of the ALS-causing mutations are 
concentrated in the Gly-rich C-terminal domain, shown to have prion-like properties, 
pathological misfolding and seeded aggregation was one of the first proposed hypothesis on 
how TDP-43 drives ALS progression (Polymenidou and Cleveland 2011; Nonaka et al. 2013).  
2.3.3. Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)  
As TDP-43, hnRNPA1 is also a member of hnRNP family, more specifically A/B subfamily 
(Bekenstein and Soreq 2013). Members of this protein family are together with histons the 
most abundant proteins in the nucleus (Bekenstein and Soreq 2013). The structure of these 
proteins allows them to interact with both proteins and RNAs, which enables them their 
major involvement in splicing, mRNA stabilization, miRNA biogenesis and transcriptional 
regulation (Bekenstein and Soreq 2013; Roy et al. 2017; Howard et al. 2018). HnRNPA1 is a 
34 kDa protein, composed of two RRMs and a glycine-rich C-terminal region, which contains 
M9 sequence (amino acids 268 to 305), involved in bi-directional shuttling between nucleus 
and cytoplasm (Bekenstein and Soreq 2013; Roy et al. 2017). HnRNPA1 is translocated into 
the nucleus by binding to Karyopherin-β2 (Transportin-1) and phosphorylation of serine 
residues near M9 sequence results in its cytoplasmic accumulation (Allemand et al. 2005; 
Twyffels, Gueydan, and Kruys 2014). C-terminal domain of hnRNPs is proposed to be 
involved in their reciprocal interaction. For example, C-terminal part of TDP-43 directly 
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interacts with C-terminal domain of hnRNPA1, creating a complex involved in splicing 
regulation (Buratti et al. 2005).  
HnRNPA1 has been shown to autoregulate its expression levels by inhibiting intron10 
splicing of its own mRNA, which results in reduction of mature mRNA (Suzuki and Matsuoka 
2017). Alternative splicing of hnRNPA1 transcript produces two isoforms, a more abundant 
34 kDa isoform and a 38 kDa isoform referred to as hnRNPA1B (Buvoli et al. 1990). The 
longer isoform retains exon 7B, containing 52 additional amino acid residues in the glycine-
rich C-terminal domain (Buvoli et al. 1990). Nuclear depletion of TDP-43 has been 
demonstrated to drive inclusion of exon 7B, producing higher levels of longer isoform, which 
turned out to be more aggregation prone and cytotoxic (Deshaies et al. 2018). In accordance 
with this observation, spinal motor neurons of ALS patients depleted of nuclear TDP-43, 
showed increased levels of hnRNPA1B and the protein was accumulated in cytoplasmic 
inclusion, which did not co-localize with TDP-43 aggregates (Deshaies et al. 2018).  
A D262V mutation in hnRNPA1 prion-like domain has been discovered in 2013, causing 
multisystem proteinopahty and ALS in an autosomal dominant fashion (Kim et al. 2013). In 
the affected muscle tissue, TDP-43 aggregates partially co-localize with hnRNPA1 (Kim et al. 
2013). Although levels of hnRNPA1 were diminished in motor neurons harboring TDP-
positive cytoplasmic inclusions, no hnRNPA1 was detected in the inclusion themselves 
(Honda et al. 2015). 
Following stress, hnRNPA1 is phosphorylated and localizes to stress granules, however, 
phosphorylation seems to be required only for cytoplasmic localization and not for targeting 
hnRNPA1 to stress granules (Allemand et al. 2005; Guil, Long, and Cáceres 2006). In contrast, 
mRNA binding seems to be crucial for hnRNPA1 recruitment to stress granules (Guil, Long, 
and Cáceres 2006). Following treatment with arsenite, ALS-linked mutant hnRNPA1 D262V 
is more rapidly recruited into stress granules in comparison to wild-type hnRNPA1. 
HnRNPA1 undergoes phase separation and can form dynamic liquid droplets, which over 
time mature into irreversible fibrils (Molliex et al. 2015; Lin et al. 2015). Fibrillization 
processes are greatly enhanced by ALS-linked mutation D262V (Kim et al. 2013; Lin et al. 
2015). Incubation with Karyopherin-β2 protein disperses liquid droplets formed by 
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hnRNPA1, inhibits hnRNPA1 fibrillization and slowly disaggregates hnRNPA1 fibrils (Guo et 
al. 2018). 
2.3.4. Matrin-3 (MATR3) 
Matrin-3 is a 125 kDa inner nuclear matrix protein with additional diffuse nuclear 
distribution. It contains several recognizable motifs including two RRMs, two zinc finger 
motifs (Znf), an NLS and NES (Zhao et al. 2018). Nuclear matrix proteins form a skeletal 
nuclear framework and are involved in chromatin organization, DNA replication, 
transcription, repair, RNA processing and transport (Belgrader, Dey, and Berezney 1991). 
Matrin-3, together with SFPQ and NONO, acts in response to DNA damage (Salton et al. 2010), 
it is involved in mRNA stability (Salton et al. 2011), regulates alternative splicing (Coelho et 
al. 2015; Attig et al. 2018) and is phosphorylated in response to N-methyl-D-aspartate 
receptor (NMDAR) activation (Giordano et al. 2005).  
A S85C mutation in MATR3 gene was first linked with Autosomal-dominant distal myopathy 
(Senderek et al. 2009). In 2014, however, an exome sequencing study reclassified mutations 
in MATR3 as familial ALS (fALS) cases (Johnson et al. 2014). Matrin-3 inclusions were 
detected in some of the affected neurons in a subset of patients, including those with a 
mutation in C9orf72 gene instead of MATR3 (Johnson et al. 2014). TDP-43 has been shown to 
interact with Matrin-3 (Ling et al. 2010; Iradi et al. 2018) and expression of disease-causing 
Matrin-3 mutations in NSC-34 cells resulted in defects of nuclear mRNA export of both global 
mRNA, as well as the mRNA of TDP-43 and FUS (Boehringer et al. 2017). A pathological study 
reported finding Matrin-3 positive staining in motor neurons of 60 % examined sALS cases 
in about 16.8 % of all TDP-43 positive inclusions. However, they couldn’t find any Matrin-3 
positive, TDP-43 negative cytoplasmic staining (Tada et al. 2018). Transiently expressing 
four ALS-linked Matrin-3 mutants in rat primary cortical neurons, as well as knocking down 
endogenous Matrin-3, resulted in increased toxicity, suggesting vulnerability to both gain or 
loss of function mechanisms (Malik et al. 2018).  
Matrin-3 has been identified as a potential component of cytoplasmic stress granule 
proteome (Jain et al. 2016). In cultured cells, it does not co-localize with G3BP1 (Ras GTPase-
activating protein-binding protein 1), a major component of stress granules (Gallego-Iradi et 
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al. 2015). However, immunofluorescent tissue analysis from ALS patients bearing S85C Matr-
3 mutation showed increased expression of TIA1 and its’ ligand G3BP1 (Palmio et al. 2016). 
Primary fibroblasts harboring S85C mutation had significantly reduced stress granule 
formation and viability following exposure to oxidative stress via sodium arsenite treatment 
(Mensch et al. 2018). 
N-terminal sequence of Matrin-3 exhibits low complexity and is able to undergo phase 
separation to form liquid-like droplets in the nucleus (Iradi et al. 2018; Gallego-Iradi et al. 
2019). Interestingly, introduction of S85C mutation inhibits droplet formation, while two 
other ALS mutations F115C and P154S have little effect on this phenomenon (Gallego-Iradi 
et al. 2019). Similarly, S85C mutation prevents assembly of TDP construct usually exhibiting 
nuclear liquid droplets (Gallego-Iradi et al. 2019).   
2.3.5. Valosin-containing protein (VCP) 
VCP or p97 is a member of AAA+ protein family of ATPases (ATPases associated with diverse 
cellular activities). They are a large and diverse superfamily, found in all organisms and 
involved in a wide variety of different functions. They use the energy released by ATP 
hydrolysis to drive molecular remodeling events (Snider, Thibault, and Houry 2008). VCP has 
a barrel-like structure, assembled from two homo-hexameric rings, one of which, following 
ATP hydrolysis, undergoes dramatic conformational changes (Xia, Tang, and Ye 2016). VCP 
is highly conserved from archaea to humans and VCP-knockout mice are not viable, 
suggesting it has a vital role within both unicellular and multicellular organisms (Müller et 
al. 2007). Its involvement in protein homeostasis is well established, as it facilitates 
proteasomal degradation of damaged or misfolded proteins by binding to polyubiquinated 
proteins, extracting them from other non-ubiquitinated proteins and delivering them to 
proteasome complex (Ye, Meyer, and Rapoport 2001; Meyer and Weihl 2014; Ye et al. 2017). 
The best studied protein degradation process is endoplasmic reticulum (ER)- associated 
degradation, a pathway where VCP is recruited to the ER membrane to capture misfolded 
proteins, which are then ubiquitinated and extracted from the membrane (Xia, Tang, and Ye 
2016). Moreover, numerous other functions have been ascribed to VCP, such as involvement 
in cellular stress response by affecting stress granule assembly (Seguin et al. 2014) and 
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promoting their clearance (Buchan et al. 2013; B. Wang et al. 2019). It is an integral part of 
lysosomal system and autophagy, and participates in regulation of critical signaling pathways 
and DNA repair and replication (Partridge et al. 2003; Ju et al. 2009; van den Boom and Meyer 
2018).  
Considering important and diverse roles of VCP in cellular processes, it is not surprising that 
mutations in VCP are associated with several human diseases, such as Inclusion Body 
Myopathy, Paget disease and Frontotemporal dementia (IBMPFD) (Watts et al. 2004) and 
ALS (Johnson et al. 2010; Abramzon et al. 2012). So far, more than 45 mutations in VCP gene 
have been identified (Saracino et al. 2018), which result in nuclear and cytoplasmic 
inclusions of TDP-43 (Forman et al. 2006; Neumann et al. 2007; Johnson et al. 2010; Ayaki et 
al. 2014). Mutations of VCP in the N-domain lead to reduced SUMOylation, impaired hexamer-
assembly and defective stress response (T. Wang et al. 2016). Studies done in fibroblasts have 
shown that VCP mutations decrease mitochondrial potential (Bartolome et al. 2013). Similar 
phenomenon was observed when mutant VCP was overexpressed in SH-SY5Y cells compared 
to wild-type VCP overexpression, confirming dominant-negative effect of the mutants 
(Bartolome et al. 2013). HeLa cells overexpressing either VCP A232E or R155H mutant had 
constitutive TDP-43-positive stress granules in the cytoplasm, indicating that stress granule 
dynamic could be a common underlying mechanism for ALS pathogenesis initiated by VCP 
mutations as well as mutations in other stress-granule promoting proteins such as TDP-43, 
FUS, hnRNPA1 and hnRNPA2B1 (Buchan et al. 2013). 
Transfection of primary mouse cortical neurons with wild-type VCP showed no difference in 
TDP-43 nuclear staining compared to control. In contrast, transfection with either VCP 
R155H or VCP A232E mutant resulted in significant clearance of endogenous TDP-43 from 
the nuclei and accumulation in the cytoplasm. There were no aggregates present in either 
compartment (Ritson et al. 2010). 
Modelling VCP pathology in ALS patients induced pluripotent stem cells (iPSCs) directly 
differentiated into motor neurons has revealed early cytoplasmic mislocalization of TDP-43 
and ER stress, followed by mitochondrial dysfunction, oxidative stress, reduced synaptic 
density, and cell death (Hall et al. 2017).  
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Drosophila melanogaster has a highly conserved VCP orthologue ter94, which is 92% similar 
and 83% identical to human VCP at the amino acid level (Ritson et al. 2010). Flies with 
neuron-specific TBPH (Drosophila ortholog of human TDP-43) knockdown overexpressing 
wild-type ter94 had improved phenotypes, whereas loss of function allele ter94 enhanced 
phenotype dysfunction induced by TBPH knockdown (Kushimura et al. 2018).  In contrast, 
another study showed no interaction between Ter94 and human wild-type TDP-43 
expressed in flies and a mild enhancement of the pathologic phenotype when co-expressing 
wild-type ter94 and NLS-mutant TDP-43 (Ritson et al. 2010). On the other hand, ter94 mutant 
R152H strongly enhanced degenerative phenotype with co-expression of either wild-type 
TPD-43, NLS-mutant TDP-43 or M337V mutant TDP-43, but not NES-mutant TDP-43 (Ritson 
et al. 2010).  
Mouse model of knock-in VCP R155H mutant revealed that frontal cortex cells expressing 
mutant protein had cytoplasmic inclusions positive for TDP-43 and ubiquitin, whereas wild-
type controls only harbored nucleic inclusions (Nalbandian et al. 2013). 
2.3.6. Ubiquilin-2 (UBQLN2) 
UBQLN2 is a 66 kDa member of ubiquilin protein family. In humans, there are four known 
ubiquilin paralogs (1, 2, 3, and 4) and each of them has a specific expression profile (Renaud 
et al. 2019). The main function of UBQLN2 is delivering ubiquitinated proteins to the 
proteasome, but it is also involved in autophagy, cell signaling, cell cycle progression and 
cytoskeletal association (Zhang et al. 2014). It contains an N-terminal ubiquitin-like domain 
(UBL), which interacts with proteasomal subunits, a C-terminal ubiquitin-associated domain 
(UBA), which interacts with ubiquitin and polyubiquitin chains and four STI-1 domains in the 
middle region of the protein (Renaud et al. 2019). A unique, C-terminal proline-rich region 
(PXX) containing 12 tandem repeats involved in protein-protein interactions, differentiates 
UBQLN2 from other members of ubiquilin family (Deng et al. 2011; Renaud et al. 2019). 
UBQLN2 undergoes liquid-liquid phase separation, which may be driven by oligomerization 
via C-terminal portion of STI1-II domain (Dao et al. 2018). These liquid droplets are then 
disassembled by binding of ubiquitin and polyubiquitinated chains to UBA domain of 
UBQLN2 (Dao et al. 2018). UBA domain is essential for liquid-liquid phase separation and it 
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promotes amyloid-like aggregation (Dao et al. 2018; Sharkey et al. 2018).  UBQLN2 associates 
with stress granule components in homeostatic and stress conditions and regulates their 
formation by delaying initiation processes (Alexander et al. 2018).  
In 2011, Deng et al. reported finding five mutations in the UBQLN2 gene, leading to X-linked 
dominant fALS (P497H, P497S, P506T, P509S and P525S). All of the mutations were present 
in the PXX repeat region, involving proline residues (Deng et al. 2011). Later, it was shown 
that all of the five mutations have longer half-lives than the wild-type protein and that they 
disrupt UBQLN2 mediated proteasomal activities (Chang and Monteiro 2015). In addition, 
ALS-linked UBQLN2 mutations change UBQLN2 liquid-liquid phase separation properties, 
affect its solubility and promote its oligomerization, however they do not hinder the ability 
of ubiquitin to disassemble UBQLN2 liquid droplets  (Kim et al. 2018; Dao et al. 2019). 
Deng and colaborators have also shown presence of UBQLN2 aggregates in other types of 
ALS, suggesting it is a common component of the inclusions in the affected tissue. However, 
not all of UBQLN2 aggregates co-localize with TDP-43 inclusions (Deng et al. 2011; Williams 
et al. 2012).  
Primary neuroglial cultures transduced with recombinant AAV2/8 virus containing either 
wild-type or mutant UBQLN2 (P497S, P497H and P506T), had low levels of diffuse protein in 
cytoplasm as well as UBQLN2-positive accumulations, although mutant UBQLN2 produced 
larger and more prevalent puncta (Ceballos-Diaz et al. 2015).  
In vitro studies have shown that UBQLN2 binds to the C-terminal domain of TDP-43 in cell 
culture and may play a role in regulating levels of TDP-43 (Cassel and Reitz 2013). UBQLN2 
also binds to the unstructured region of hnRNPA1 and evidence supports its role in 
stabilization of hnRNPA1 protein (Gilpin, Chang, and Monteiro 2015). Interestingly, UBQLN2 
proteins harboring ALS mutations in PXX region have shown reduced binding to hnRNPA1 
as well as hnRNPA1 D262 mutant failed to bind wild-type UBQLN2, potentially connecting 
ALS causing proteins involved in proteolysis and RNA-binding  (Gilpin, Chang, and Monteiro 
2015). 
Expression of two copies of UBQLN2 P487H or P525S mutant in Drosophila melanogaster led 
to age-dependent loss of interommatidial bristles and hyperpigmented eye patches whereas 
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two copies of wild-type UBQLN2 resulted in only mild bristle loss and few smaller eye patches 
(Kim et al. 2018). Interestingly, their UBQLN2 P4X construct harboring four ALS mutations, 
which was shown to be dramatically less soluble, manifested neither bristle loss nor eye 
patches, indicating that the eye toxicity of UBQLN2 is not directly linked to its aggregation 
potential (Kim et al. 2018). Co-expression of wild-type UBQLN2 with TDP-43 M337V showed 
no exacerbation of TDP-43 mediated eye degeneration, whereas UBQLN2 P525S mutant 
worsened the eye phenotypes (Kim et al. 2018). All of the UBQLN2 transgenes have shown 
progressive aggregation in the cytoplasm of neurons, however, wild-type UBQLN2 
aggregation never reached levels seen in P487H or P4X mutants (Kim et al. 2018). 
UBQLN2 mouse model displaying motor neuron disease and cognitive deficits revealed 
reduced TDP-43 nuclear staining in motor neurons expressing P497S and P506T mutants 
and inclusions in their cytoplasm positive for TDP-43, ubiquitin and UBQLN2 (Le et al. 2016). 
In a different mouse model, UBQLN2 P506T mutant accumulated in large, irregular 
cytoplasmic inclusions with no detectable diffuse protein. TDP-43 aggregates were also 
present in the cytoplasm, however, they were distinct from UBQLN2 inclusions and no 
significant TPD-43 redistribution from the nucleus was observed (Sharkey et al. 2018). 
Introduction of wild-type UBQLN2 and P497S, P497H or P506T mutants via bilateral 
injection of AAV2/8 into mouse P0 brains resulted in widespread neuronal specific 
expression. Wild-type UBQLN2 in neurons was diffuse with few small punctate cytoplasmic 
accumulations. In contrast, all of the mutants formed large intracellular neuronal inclusions. 
However, only mice expressing P506T mutant presented cytoplasmic TDP-43 pathology 
associated with UBQLN2-positive accumulations (Ceballos-Diaz et al. 2015). 
2.4. Proposed Mechanisms of ALS Onset and Progression 
2.4.1. Protein Misfolding and Seeded Aggregation 
Protein misfolding and deposition of incorrectly folded proteins into insoluble inclusions are 
characteristic pathological features of neurodegenerative disorders; hence, these conditions 
are also called “protein misfolding disorders” or proteinopaties. However, different proteins 
may be main components of pathological inclusions in the affected cells of patients with 
different diagnosis, although there is some overlap. Proteins are inclined to misfold due to 
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their protein structure and they typically harbor low complexity domains (LCDs), involved 
in liquid-liquid phase separation (LLPS) (Bräuer, Zimyanin, and Hermann 2018).   
Protein structure is defined by the amino acid sequence, secondary structures such as α-
helices and β-sheets and tertiary globular structure, where exposure of hydrophobic regions 
to the solvent is minimized (Parakh and Atkin 2016). The process of protein misfolding leads 
to conformational changes, which result in the exposure of the hydrophobic core and in the 
increase of β-sheet proportion in the protein. Protein aggregation is an auto-catalytic process 
as misfolded proteins act as seeds of aggregation by templating and sequestering natively-
folded proteins into larger inclusions (Parakh and Atkin 2016). These pathological 
assemblies form at initiation sites and then spread to other locations of the nervous system 
following a relatively predictable sequence unique to the principle protein characteristic of 
the disease (Z. Zhang, Nie, and Chen 2018). 
Similar is typical for ALS; the symptoms usually begin in discrete body regions, displaying 
various upper and lower motor neuron involvement. The pathology then propagates to 
neighboring neuroanatomical regions or within neuronal networks (Ravits et al. 2013). 
Postmortem studies implicate spreading of TDP-43 aggregates via neuronal projections 
possibly by transsynaptic transmission. On the other hand, in vitro studies suggest direct cell-
to-cell propagation for example via exosomes (Riku 2020). Seeded aggregation and 
transmission of the pathological inclusions have been already demonstrated in vitro (Nonaka 
et al. 2013; Ding et al. 2015; Gasset-Rosa et al. 2019) and in vivo in mouse model (Porta et al. 
2018).  
As mentioned previously, most of the ALS-associated mutations in TDP-43 are concentrated 
in its C-terminal domain with LCD characteristics (Bräuer, Zimyanin, and Hermann 2018). 
These mutations increase the propensity of TDP-43 to misfold, however, aggregates 
extracted from brains and spinal cord of ALS patients without pathogenic mutations have 
also seeding ability in vitro (Bräuer, Zimyanin, and Hermann 2018). In accordance with the 
principle of autocatalytic templating, only TDP-43 fibrils can act as seeds for nucleation of 
native TDP-43 protein. Neither α-synuclein fibrils nor SOD1 aggregates were able to 
sequester wild-type TDP-43 into inclusions (Furukawa et al. 2011; Nonaka et al. 2013). 
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There is a long-standing debate over whether TDP-43 aggregates are toxic or might have a 
protective role by sequestering soluble oligomers and preventing formation of liquid-like 
condensates (Hergesheimer et al. 2019). Recently, a study analyzing more than 50.000 
mutations in the disordered region of TDP-43 uncovered that increasing hydrophobicity and 
consequently aggregation, strongly reduce its toxicity in yeast (Bolognesi et al. 2019). 
2.4.2. Liquid-Liquid Phase Separation (LLPS) and Stress Granule Assembly 
In the recent years, LLPS has emerged as a ubiquitous principle of cellular organization by 
compartmentalization and concentration of bio macromolecules into distinct condensates, 
involved in biological processes ranging from gene expression to cell division (Hondele et al. 
2020; Noda, Wang, and Zhang 2020). Numerous membraneless organelles, such as signaling 
clusters, processing bodies (P-bodies), nuclear speckles, stress granules, and germline 
granules are thought to assemble via LLPS (Noda, Wang, and Zhang 2020). LLPS is a dynamic 
physical process occurring in highly concentrated protein solution in which protein 
spontaneously separates into a dense and dilute stable phases (Dobra et al. 2018). The key 
determinant driving protein phase separation is presence of adhesive components allowing 
multivalent interactions between molecules (Dobra et al. 2018).  
Cells respond to stressful stimuli such as changes in pH, viral or bacterial exposure, lack of 
metabolites and increased oxidative stress in variety of ways. One of these mechanisms is 
temporary shutdown of global translation and stress granule assembly (Sidibé and Vande 
Velde 2019). Stress granules are highly dynamic membraneless structures providing 
protection to translationally arrested polyadenylated mRNAs and certain components of the 
translational machinery, allowing rapid reinitiation of translation as soon as the stress 
subsides (Sidibé and Vande Velde 2019).  
They are not uniform assemblies and contain internal sub structures organized into two 
layers; a more stable internal core harboring RBPs with low-complexity domains (LCD) and 
a less concentrated shell, which behaves as a liquid-liquid phase separation (Wheeler et al. 
2016; Protter and Parker 2016; Dobra et al. 2018). Phase separation in stress granules is 
enabled by a combination of RNA-RNA interactions, protein-protein interactions, and RNA-
protein interactions (Youn et al. 2019): 
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● Stress granules have higher RNA concentration in comparison with surrounding 
cytoplasm, which increases the chance of RNA-RNA interactions through Watson-
Crick base-pairing, non-canonical base-pairing, and helical stacking; 
● RBPs harboring LCDs are recruited to stress granules. They bind to RNA, while also 
participate in interactions with other LCD containing proteins (Dobra et al. 2018). 
Stress granules recapitulated in cellular models are usually highly dynamic structures. They 
assemble rapidly in response to cellular stress and dissociate soon after the stressor is 
removed (Babinchak and Surewicz 2020). However, any disturbance of this process could 
have drastic impact on stress granule dissociation, especially the dense core comprising 
aggregation prone RBPs, which could then evolve into solid aggregates such as pathological 
inclusions found in neurodegenerative disorders (Babinchak and Surewicz 2020; Dobra et al. 
2018). Indeed, mutations in several proteins involved in stress granule dynamics such as 
TDP-43, FUS, TIA1, MATR3, hnRNPA1 and hnRNPA2, EWSR1 and UBQLN2 have been linked 
to ALS and other neurodegenerative diseases (Sreedharan et al. 2008; Deng et al. 2011; 
Couthouis et al. 2012; Vance et al. 2013; Kim et al. 2013; Johnson et al. 2014; Mackenzie et al. 
2017). Mutations in these proteins are often found in their LCD domains, which can increase 
their tendency to phase separate (Advani and Ivanov 2020). It has been proposed, that the 
mutant proteins might cause assembly of less dynamic, chronic, more fibrillary and 
persistent subtypes of stress granules, leading to compromised RNA metabolism, protein 
quality control and promotion of apoptosis (Advani and Ivanov 2020). Another consequence 
of persistent cytoplasmic stress granules is sequestration of specific RNA-binding proteins in 
cytoplasmic foci, possibly compromising their normal cellular function such as RNA 
processing, transport and translation (Advani and Ivanov 2020). 
However, recent study has shown that rather than cytoplasmic, TDP-43 forms dynamic, 
reversible, liquid droplet-like nuclear bodies in response to oxidative stress, which are 
thought to alleviate TDP-43-mediated cytotoxicity (Wang et al. 2020). Moreover, Gasset-Rosa 
and colleagues have recently shown that transient exposure of cells to sonicated TDP-43 
fibrils can induce cytoplasmic TDP-43 de-mixing, leading to liquid droplet formation, distinct 
from stress granules (Gasset-Rosa et al. 2019). These TDP-43 droplets did not contain any 
classical stress granule markers (TIA-1, G3BP1 or UBAP2L) or RNA, however, they 
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accumulated components critical for cytoplasmic transport such as RanGap 1, leading to 
nuclear clearance of wild-type TDP-43 within a month (Gasset-Rosa et al. 2019).  Similar lack 
of stress granule components and mRNA was revealed in a subset of cytoplasmic TDP-43 
granules following arsenite treatment (Mann et al. 2019). What is more, these TDP-43 
inclusions were hyperphosphorylated and p62-positive, two of the pathological hallmarks of 
TDP-43 proteinopathy (Mann et al. 2019). Both of these studies suggest that TDP-43 
recruitment to stress granules requires mRNA binding, leading to dynamic, reversible and 
more soluble cytoplasmic puncta, while deposits lacking RNA and stress granule components 
are irreversible, toxic and reminiscent of pathological inclusions from patients suffering from 
TDP-43 proteinopathies.  
2.4.3. Disruption of Nucleocytoplasmic Transport 
Nucleocytoplasmic transport is a process of exchanging proteins, RNA and other cargoes 
between nucleus and cytoplasm. Three main groups of proteins participate in this process: 
1. Nucleoporins, which make up the nuclear pore complex (NPC) physically connecting 
nucleoplasm and cytoplasm. 
2. Nuclear transport receptors, which chaperone RNA and protein cargo through the 
nuclear pore, 
3. Small GTPase Ras-related nuclear protein (Ran) with associated Ran GTPase-
activating protein (RanGAP) and Ran guanine nucleotide exchange factor (RanGEF) 
provide energy and govern the directionality of the transport (Fallini et al. 2020).  
NPCs are large multiprotein complexes, providing a semi-permeable separation between 
nucleus and cytoplasm and tightly controlling shuttling of protein cargo (Fallini et al. 2020). 
NPC is assembled from 500 – 1000 proteins, which are multiple copies of about 30 unique 
proteins called nucleoporins (Moore, Rabichow, and Sattler 2020). Intrinsically disordered 
phenylalanine-glycine rich repeats provide diffusion barrier, allowing passive diffusion of 
small molecules (<40 kDa) but making it energetically inefficient for larger molecules (>40 
kDa) (Moore, Rabichow, and Sattler 2020).  
Nuclear transport receptors facilitate import and export of proteins through the NPC, and are 
mostly members of the Karyopherin-β family (KPNB), also known as importins and exportins 
(Kim and Taylor 2017). Large proteins destined for the nucleus usually have NLS or NES, 
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specific sequences recognized by nuclear transport receptors (Moore, Rabichow, and Sattler 
2020). Three different mechanisms of  nucleocytoplasmic transport are known, involving 
three different groups of transport receptors, namely Karyopherin α/β transport (Figure 4, 
KPNA/B1 import), Transportin transport (Figure 4, TNPO import), and Exportin transport 
(Figure 4, mRNA and protein export) mediating transport of distinct protein and RNA cargoes 
(Moore, Rabichow, and Sattler 2020).  
Ran protein binds to importins and exportins enabling them to transport their cargo across 
the nuclear membrane depending on its nucleotide state. RanGEF  is preferentially located in 
the nucleus, whereas RanGAPs and Ran-binding proteins (RanBPs) catalyzing the hydrolysis 
of GTP to GDP are localized exclusively to the cytoplasm (Kim and Taylor 2017). This 
intracellular distributions leads to higher levels of RanGTP in the nucleus and RanGDP in the 
cytosol, providing a gradient utilized by importins and exportins to determine the direction 
of the nucleocytoplasmic transport (Kim and Taylor 2017). 
The whole process starts in the cytoplasm, where import-associated KPNBs bind the NLS on 
the cargo or cargo complex and then translocate across the NPC into the nucleus (Prpar 
Mihevc et al. 2017). In the nucleus, RanGTP binds to import-associated KPNBs, releasing the 
cargo. Finally, KPNBs-RanGTP complex is recycled back to the cytoplasm, where GTP is 
hydrolyzed to GDP, causing the dissociation of Ran from KPNBs. Nuclear export starts with 
KPNBs binding to the cargo’s NES and RanGTP to translocate to the cytoplasm. Right after 
GTP hydrolysis, cargo is released in the cytoplasm and nuclear export KPNBs and RanGDP 
are recycled back into the nucleus (Figure 4) (Prpar Mihevc et al. 2017). 
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Figure 4: Mechanisms of nucleocytoplasmic shuttling of proteins. KPNA/B1) Adaptor proteins 
karyopherins-α bind to the cargo and together with karyopherin-β translocate into the nucleus, where RanGTP 
binds to both units and dissociates the complex. Karyopherins-α need additional factor called CAS (cellular 
apoptosis susceptibility) to exit the nucleus. TNPO) Transportin-1 binds directly to the NLS of the cargo protein 
and translocates into the nucleus, where RanGTP binds to the complex, dissociates it and takes importin-1 back 
to the cytoplasm. mRNA and protein export) Protein export is mediated by cooperative association in the 
nucleus of RanGTP, nuclear export signal-containing cargo and a karyopherin CRM1 (chromosome region 
maintenance 1 protein homologue). On the cytoplasmic side, hydrolysis of GTP bound to Ran results in 
dissociation of the complex and delivery of the cargo to the cytoplasm (Prpar Mihevc et al. 2017) (with 
permission from Oxford University Press). 
One of the most prominent features of ALS and FTLD is mislocalization of nuclear proteins 
into cytoplasmic deposits, indicating dysfunction of nucleocytoplasmic transport as a 
possible mechanism of disease onset. Two of such proteins are TDP-43 and FUS, which is 
mutated in approximately 1 % of sALS and up to 5 % of fALS cases (Naumann et al. 2019). At 
its C-terminus, FUS harbors a PY-NLS, which interacts with Transportin-1, leading to its 
nuclear import (Prpar Mihevc et al. 2017). Most of the ALS-causing FUS mutations are 
clustered in its NLS, promoting pathological cytoplasmic localization of FUS (Vance et al. 
2013). The degree to which these mutations disturb normal nucleocytoplasmic transport 
correlates with the disease severity; more dramatic redistribution of FUS into the cytoplasm 
leads to earlier disease onset and more aggressive progression (Kim and Taylor 2017). 
Moreover, NLS can be posttranslationally modified, affecting its interaction with 
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Transportin-1, leading to its cytoplasmic accumulation (Prpar Mihevc et al. 2017). For 
example, it has been shown that phosphorylation of the C-terminal tyrosine residue at the 
position 526 abolishes interactions between Transportin-1 and FUS, disrupting its nuclear 
import (Darovic et al. 2015).   
In contrast to FUS, only one TDP-43 disease-causing mutation can be found in its NLS (Kapeli, 
Martinez, and Yeo 2017), suggesting a less obvious relationship with the nucleocytoplasmic 
transport defects. TDP-43 can bind to all of the five tested Karyopherins-α and the tripartite 
complex with Karyopherin-β1 is then actively imported into the nucleus. In the nucleus, 
RanGTP binds to the complex, causing its dissociation. RanGTP with bound Karyopherin-β1 
is translocated back in the cytoplasm, Karyopherins-α, however, in addition to RanGTP 
require another export factor known as CAS (Prpar Mihevc et al. 2017). Nishimura and 
colleagues have shown reduced levels of CAS protein and to lesser extend Karyopherin-α2 in 
the brains of patients with FTD-TDP, indicating that this could contribute to cytoplasmic 
retention and aggregation of TDP-43 (Nishimura et al. 2010). However, no such evidence was 
found in ALS spinal cord tissue (Nishimura et al. 2010), although irregularities in the nuclear 
envelope and loss of nuclear Karyopherin-β1 in the anterior horn cells of sporadic ALS cases 
indicates a potential role of nuclear transport defects in ALS (Kinoshita et al. 2009). A recent 
study has shown that cytoplasmic inclusions of TDP-43 protein, caused by the introduction 
of sonicated FUS fibrils, provoked accumulation of components of nucleocytoplasmic 
transport such as RanGAP1, Ran, Nup107, Nup62 and Importin-α in the cytoplasm (Gasset-
Rosa et al. 2019). Similar observations were reported in a study expressing C-terminal TDP-
43 fragments, which caused cytoplasmic aggregation and mislocalization of Nups and 
transport factors (Chou et al. 2018) leading to disruption of nucleocytoplasmic transport and 
consequently opening the door for further exacerbation of TDP-43 mislocalization.  
2.4.4. Protein Degradation Processes 
Cellular function critically depends on proteome integrity, which is based on protein 
production, trafficking and degradation (Yerbury, Farrawell, and McAlary 2020). Due to their 
incredibly large size, motor neurons are extremely sensitive to changes in proteome 
homeostasis, leading to synaptic dysfunction and subsequent disruption of neuronal 
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connectivity by decreasing synapse number and impairing neurite outgrowth (Yerbury, 
Farrawell, and McAlary 2020). Moreover, growing genetic evidence is implicating proteome 
imbalance as one of the fundamental processes underlying cellular dysfunction and death in 
ALS (Yerbury, Farrawell, and McAlary 2020). All of this, together with the cytoplasmic 
deposits of insoluble protein aggregates in the affected neurons, indicates that protein 
degradation and proteome collapse could be a trigger for the disease onset (Yerbury, 
Farrawell, and McAlary 2020) 
Two main pathways of protein degradation implicated in ALS are ubiquitin proteasome 
system (UPS) and autophagy. Ubiquitination of proteins starts when E1 activates ubiquitin 
(Ub) in an ATP-dependent manner.  Ub is then transferred to E2 and then via E3 to the target 
protein (Maurel et al. 2018). Finally, a poly-ubiquitin chain is linked to the target protein, 
which is then degraded by the 26S proteasome, a multi-subunit complex with one 20S 
domain and two 19S domains (Maurel et al. 2018). Several findings have implicated 
deregulation of UPS in ALS: 
1. Ubiquitin is found in cytoplasmic inclusions of fALS and sALS patients, together with 
other components of proteasome. 
2. Impaired proteasomal function has been observed in ALS. 
3. Mutated genes associated with ALS have active role in UPS, such as UBQLN2 and VCP 
(Maurel et al. 2018). 
Autophagy is the second pathway of protein degradation, wherein newly formed double-
membrane vesicles named autophagosomes engulf long-lived proteins or organelles and 
transfer them to lysosomes for degradation (Corti et al. 2020). Autophagy has two primary 
duties: providing new building blocks through turnover of cellular constituents in times of 
metabolic stress and degradation of surplus or damaged organelles, aberrant or aggregated 
proteins and cytosol-invading pathogens (Strohm and Behrends 2020). Aggregated proteins 
are a poor substrate for degradation by UPS, therefore protein inclusions are primarily 
turned over by autophagy (Strohm and Behrends 2020). The formation of these aggregates 
is a normal physiological process; cells continuously utilizes quality control mechanisms to 
degrade misfolded proteins to avoid inclusion formation, or clears already formed aggregates 
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(Ramesh and Pandey 2017). However, the persistence of the cytoplasmic deposits in affected 
neurons indicates a disruption of the mechanisms of protein turnover and aggregate 
clearance in ALS (Ramesh and Pandey 2017). These pathological aggregates are then able to 
promote aberrant cellular interactions between proteins, sequestering them into the 
aggregates, thus preventing their normal function, which can result in cytotoxicity and 
eventually in cellular death (Ramesh and Pandey 2017). Additionally, several ALS-associated 
genes are directly or indirectly connected to autophagy: OPTN, UBQLN2 and SQSTM1 are 
known autophagy receptors, TBK1, C9orf72, CCNF (Ub E3 ligase substrate adaptor cyclin F), 
ALS2 (Rho guanine exchange factor) and VAPB are associated with autophagy initiation and 
regulation (Strohm and Behrends 2020). Others such as VCP have functions in 
autophagosome maturation, autophagosome-lysosome fusion, transport of autophagosomes 
and lysosome reformation (Strohm and Behrends 2020). 
2.4.5. Convergent Mechanisms of the Disease Onset and Progression 
Despite all of the discussed potential mechanisms of ALS onset and progression, we still do 
not have a clear answer to a major question: What causes TDP-43 to mislocalize from the 
nucleus to the cytoplasmic inclusions? Instead, numerous processes mediating the 
degeneration and death of motor neurons have been proposed. It is likely that an interplay 
of different mechanisms rather than a single initiating event contribute to the disease onset 
and progression. This is evident from the intertwining processes of liquid-liquid phase 
separation following stress, leading to insoluble cytoplasmic deposits, which can cause 
defects in nucleocytoplasmic transport, exacerbated by impaired degradation machinery, 
resulting in widespread aggregation propagated in a prion-like fashion throughout the 
neuronal connectome. Taken all this together, is difficult to discern contributions of the 
individual process to the disease onset and progression. However, understanding how 
different pathways converge might prove unavoidable for successful development of 
therapeutics.   
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3. Aim and Hypotheses 
In the recent years, a consensus in the ALS research community that cytoplasmic inclusions 
of TDP-43 exhibit prion-like characteristics has been established (Nonaka and Hasegawa 
2020). Seeding and intercellular propagation of aggregation between cells in vitro and in vivo 
is typical for prion-like proteins. Additionally, TDP-43 aggregates extracted from ALS and 
FTD diseased brains have been shown to adopt different conformations and have distinct 
properties, reminiscent of prion strains  (Furukawa et al. 2011; Nonaka et al. 2013; Smethurst 
et al. 2016; Porta et al. 2018; Laferrière et al. 2019). It has been proposed, that alternate 
pathological conformations may form the basis for the diversity of TDP-43 proteinopathies 
and heterogeneity of the disease progression (Laferrière et al. 2019). There is some reported 
difference between aggregate deposits in FTD with mutations in progranulin and C9orf72 
(Takeda, Kitagawa, and Arai 2020). However, the role of ALS-associated genes, the possible 
impact of their mutations on TDP-43 aggregate behavior and properties remains largely 
unknown. Hence, in this study, we sought to compare the impact of several wild-type and 
mutated ALS-associated genes on TDP-43 aggregation in vitro. 
The hypotheses we explored in this study focus on two aspects of TDP-43 aggregation. On 
the impact ALS-associated genes display on TDP-43 aggregation: 
Expression of genes (UBQLN2, MATR3, VCP and hnRNPA1) linked to ALS affects 
biochemical properties and/or cellular localization of protein TDP-43. 
On the cytoplasmic localization of TDP-43 aggregates: 
Nucleo-cytoplasmic transport defect modelling exacerbates pathological changes 
resulting from the expression of a certain ALS-associated mutation.  
The majority of the research was performed at Jožef Stefan Institute, Department of 
Biotechnology in Ljubljana. Part of the study was done at Ludwig Cancer Research in 
Cleveland Lab in San Diego. Results of this study were published in the following paper: 
Bajc Česnik A, Motaln H, Rogelj B. The Impact of ALS-Associated Genes hnRNPA1, MATR3, VCP 
and UBQLN2 on the Severity of TDP-43 Aggregation. Cells, 2020, 9(8). PMID: 32731393 DOI: 
10.3390/cells9081791 
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4. Materials and Methods 
4.1. Plasmid Preparation 
4.1.1. TDP-43 Constructs 
To track TDP-43 aggregates in cells, they had to be fluorescently tagged. To this end, mKO2-
C1 plasmid was ordered from Addgene (#54494, deposited by Michael Davidson & Atsushi 
Miyawaki (Sakaue-Sawano et al. 2008)) and TDP-43 gene was cloned from previously 
published plasmid (Ling et al. 2010) into mKO2-C1 plasmid. Primers were ordered from IDT 
and Phusion™ High-Fidelity DNA Polymerase (Thermo Fisher Scientific) was used for PCR 
reaction (Table 1,  
Table 2 and  
Table 3). 
Table 1: Primer sequences used for PCR reaction.  
Primer Name Sequence 
SalI koz TDP-43 Fw AAA AGT CGA CGC CAC CAT GGC CTC TGA ATA TAT TCG GGT AAC 
TDP-43 BamHI Rev AAA GGA TCC GGC ATT CCC CAG CCA GAA GAC TTA G 
 
Table 2: Components of PCR reaction mix. 
5x Phusion HF Buffer 10 µL 
10 mM dNTP 1 µL 
10 µM Fw Primer  2.5 µL 
10 µM Rev Primer 2.5 µL 
100 µg/mL Template DNA 1 µL 
Phusion DNA polymerase (2U/uL) 0,5 µL 
DMSO 1.5 µL 
dH2O 31 µL 
Total 50 µL 
 
Table 3: Cycling conditions. 
Temperature Time Step 
98 °C 30 s Initial denaturation 
98 °C 10 s 
30 Cycles 
55 °C 30 s 
72 °C 1 min 
72 °C 10 min Final extension 
4 °C ∞ Hold 
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Multiplied gene was separated from other components with 1 % agarose gel electrophoresis. 
4.1.2. Agarose Gel Electrophoresis 
Samples were run on 1 % agarose gel (Thermo Fisher Scientific) made with TAE buffer (40 
mM Tris, pH 8.0, 20 mM acetic acid (Fluka), 1 mM EDTA) supplemented with SYBR Safe DNA 
Gel Stain (Thermo Fisher Scientific) allowing to visualize DNA under UV-light. The samples 
were mixed with 6x DNA-loading buffer (Thermo Fisher Scientific) and GeneRuler DNA 
Ladder (Thermo Fisher Scientific) was run on the gel as well to assess the sizes of DNA 
samples. The electrophoresis was run at 100 V for 40 min. DNA fragments were then 
visualized by UV light, cut from the gel and then purified using NucleoSpin Gel and PCR Clean-
up kit (Macherey-Nagel). 
4.1.3. Plasmid Digestion and Ligation 
Both, TPD-43 insert and pKO2-C1 plasmid were digested with SalI-HF (NEB) and BamHI-HF 
(NEB) according to manufacturer’s instructions. Following heat-inactivation, linearized 
plasmid was run on the gel again and then purified with NucleoSpin Gel and PCR Clean-up 
kit. Cut TDP-43 gene was only purified, using the same kit. Both components were ligated at 
16 °C overnight with T4 DNA Ligase (NEB). The next day, 5 µL of ligation reaction was 
transformed into in-house prepared DH5α competent bacteria. 
4.1.4. Transformation of Bacteria E. coli DH5α 
50 µL aliquot of frozen bacteria E. coli DH5α was thawed on ice for 10 min. Then 5 µL of the 
ligation product was added to the thawed bacteria and they were incubated with the ligation 
mixture on ice for 30 min. To allow the assembled plasmids to enter the bacteria, heat-shock 
at 42 °C for 30 s was performed and further 10 min incubation on ice followed. Nutrient-rich 
microbial broth S.O.C. was added to the bacteria, and they were shaken for 1 h at 37 °C. Then 
the bacteria were spin with a tabletop centrifuge, collected at the bottom of the Eppendorf 
tubes and plated on LB agar plate containing ampicillin (LBA). Six colonies were picked and 
grown overnight in 5 mL LBA media. Plasmids were purified from bacterial culture with 
NucleoSpin Plasmid kit (Macherey-Nagel). Plasmid concentrations were determined by 
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Nanodrop analysis (Thermo Fisher Scientific) and the correct sequences were confirmed by 
sequencing (Eurofins Genomics).  
As a backbone, plasmid pcDNA5/FRT/TO from Thermo Fischer Scientific was selected 
(Figure 5), allowing us to prepare FlpIn cell line, if necessary.  
 
Figure 5: Summary of the main features of pcDNA5/FRT/TO plasmid. Hygromycin resistance gene lacks its 
native ATG codon, thus transfection of the plasmid in a cell line alone, does not provide cells with the resistance 
to the antibiotic. The inserted gene of interest is inducibly expressed under the control of a hybrid CMV/TetO2 
promoter.  
4.1.5. Plasmid Assembly by CloneEZ PCR Cloning Kit  
CloneEZ PCR Cloning Kit (GenScript) was selected for insertion of KO2- TDP-wt construct 
into pcDNA5/FRT/TO plasmid. The kit allows assembling several target DNA fragments into 
a linearized vector using homologous recombination. The fragment of interest should be 
multiplied by PCR using primers with an add-on of 15 base sequences homologous to either 
side of the restriction site that is used to linearize the vector. As we wanted to have an option 
to detect the protein with an antibody, we added a sequence for HA-tag at the C-terminal of 
TDP-43 (Table 4).  
Table 4: Primer sequences used for PCR reaction.  
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Primer Name Sequence 
FRT KO2 Fw GTT TAA ACT TAA GCT GCC ACC ATG GTG AGT GTG AT 
TDP HA Rev TAG ACT CGA GCG GCC TCC CTA AGC GTA ATC TGG AAC ATC GTA TGG GTA CAT 
TCC CCA GCC AGA AGA CTT AGA  
Following PCR reaction, the target sequence was run on gel and purified. Plasmid 
pcDNA5/FRT/TO was linearized with HindIII in NotI (Thermo Fisher Scientific), run on gel 
and purified. CloneEZ reaction was mixed in an Eppendorf tube (Table 5). 
Table 5: CloneEZ reaction mix. 
Linearized vector  (100-200 ng/µL) 3µL 
Purified PCR products (30 ng/µL) 4 µL 
10x CloneEZ Buffer 1 µL 
CloneEZ Enzyme 1 µL 
dH2O 1 µL 
Total 10 µL 
 
The reaction was incubated at 22 °C for 30 min and then transferred to the ice for five 
minutes. Then, the mixture was transformed into DH5α competent bacteria (see 4.1.4). The 
next day, 6 colonies were selected for plasmid isolation and correct plasmid sequence was 
determined by sequencing.  
Similarly, pcDNA5/FRT/TO/KO2-only plasmid was generated (Table 6). 
Table 6: Primer sequences used for PCR reaction. 
Primer Name Sequence 
FRT KO2 Fw GTT TAA ACT TAA GCT GCC ACC ATG GTG AGT GTG AT 
KO2 only Rev AAACGGGCCCTCTAGACTCGAGCTAATGAGCTACTGCATCTTCTACCTG 
 
4.1.6. Site-Directed Mutagenesis 
Site-directed mutagenesis is a method used to make specific and targeted changes to the DNA 
sequence. To introduce a mutation in a double-strand plasmid, complementary pair of 
oligonucleotides, containing the desired nucleotide change needs to be synthesized. The 
primers are used to amplify the entire plasmid in a thermocycling reaction with a high-
fidelity non-strand-displacing DNA polymerase. The mutation may be a single base change (a 
point mutation), multiple base changes, deletion, or insertion. The template DNA is 
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eliminated from the reaction mixture by restriction enzyme such as DpnI, which specifically 
digests methylated DNA. Plasmids isolated from most E. coli strains are methylated and 
would therefore, be digested, while the plasmid produced in vitro is unmethylated and would 
be left undigested. In this thermocycling reaction, DNA is not exponentially amplified.  
To generate two different ALS mutation and to delete NLS signal from TDP-43 sequence, site-
directed mutagenesis was performed on pcDNA5/FRT/TO/KO2-TDP-wt plasmid (Table 7, 
Table 8 and Table 9). 
Table 7: Primer sequences used for site-directed mutagenesis. Sites of the nucleotide change are in small 
caps and underlined. 
Primer Name Sequence 
TDP dNLS Fw GTG TAT GTT GTC AAC TAT CCA AAA GAT AAC GCA GTC CAG AAA ACA TCC 
G TDP dNLS Rev CGG ATG TTT TCT GGA CTG CGT TAT CTT TTG GAT AGT TGA CAA CAT ACA 
C TDP-43 M337V Fw GCA CTA CAG AGC AGT TGG GGT ATG gTG GGC ATG TTA GCC AGC CAG C 
TDP-43 M337V Rev GCT GGC TGG CTA ACA TGC CCA cCA TAC CCC AAC TGC TCT GTA GTG C 
TDP-43 Q331K Fw CCG CCC AGG CAG CAC TAa AGA GCA GTT GGG GTA TGA TGG G 
TDP-43 Q331K Rev CCC ATC ATA CCC CAA CTG CTC TtT AGT GCT GCC TGG GCG G 
 
Thermocycling reaction was performed with PfuTurbo DNA Polymerase (Agilent). 
Table 8: Components of thermocycling reaction mix for site-directed mutagenesis.  
10× Cloned Pfu DNA buffer 5 µL 
DNA template (50 ng/µL) 1 µL 
10 µM Fw Primer 1 µL 
10 µM Rev Primer 1 µL 
10 mM dNTP 1 µL 
dH2O 40 µL 
PfuTurbo DNA Polymerase (2.5 U/µL) 1 µL 
Total 50 µL 
  
Table 9: Cycling conditions for site-directed mutagenesis.  
Temperature Time Step 
95 °C 2 min Initial denaturation 
95 °C 30 s 
25 Cycles 
55 °C 1 min 
72 °C 6 min 
72 °C 10 min Final extension 
4 °C ∞ Hold 
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As the template plasmid was isolated from a dam+ E. coli strain, the parental strands were 
suitable for DpnI (NEB) digestion (Table 10).  
Table 10: Reaction mixture for DpnI digestion.  
PCR product 8 µL 
10x CutSmart Buffer 1 µL 
DpnI Restriction Enzyme 1 µL 
Total 10 µL 
 
The reaction was incubated at 37 °C for 1 h and then DH5α competent bacteria were 
transformed with 5 µL of the mixture (see 4.1.4). Several colonies were selected for plasmid 
purification. Correct sequence was determined by sequencing. 
To study TDP-43 aggregation, several dNLS fragments were prepared by site-directed 
mutagenesis (see 4.1.6 and Table 11).  
Table 11: Primer sequences used for site-directed mutagenesis. Sites of the nucleotide change are in small 
caps and underlined.  
Primer Name Sequence 
TDP mut FW ATG GGC ATG TTA GCC AGC CAG tAG AAC CAG TCA GGC CCA T 
TDP mut Rev ATG GGC CTG ACT GGT TCT aCT GGC TGG CTA ACA TGC CCA T 
TDP Funct Fw CGA ACC TAA GCA CAA TAG CAA TtG ACA GTT AGA AAG AAG TGG AAG ATT 
TGG TDP Funct Rev CCA AAT CTT CCA CTT CTT TCT AAC TGT CaA TTG CTA TTG TGC TTA GGT 
TCG TDP half Gly Fw GCA GAG GGG GTG GAG CTG GTT TGt GAA ACA ATC AAG GTA GTA ATA TGG 
GTG G TDP half Gly Rev CCA CCC ATA TTA CTA CCT TGA TTG TTT CaC AAA CCA GCT CCA CCC CCT 
CTG C  
To have the same tags for all of the constructs, HA-tag was eliminated from full-length TDP-
43 gene by insertion of stop codon via site-directed mutagenesis (Table 12, Table 13 and 
Table 14).  
Table 12: Primer sequences used for site-directed mutagenesis. Sites of the nucleotide change are in small 
caps and underlined.  
Primer Name Sequence 
FwTDPstop CTTCTGGCTGGGGAATGtagTACCCATACGATGTTCCAG 
RevTDPstop CTGGAACATCGTATGGGTActaCATTCCCCAGCCAGAAG 
 
Thermocycling reaction was performed with KOD Hot Start polymerase (Merck Millipore). 
Table 13: Components of the thermocycling reaction mix for site-directed mutagenesis. 
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10× KOD Hot Start Buffer 5 µL 
DNA template (100 ng/µL) 1 µL 
10 µM Fw Primer 1.5 µL 
10 µM Rev Primer 1.5 µL 
10 mM dNTP 5 µL 
DMSO 2.5 µL 
25 mM MgSO4 3 µL 
dH2O 29.5 µL 
KOD Hot Start Polymerase (1 U/µL) 1 µL 
Total 50 µL 
 
Table 14: Cycling conditions for site-directed mutagenesis.  
Temperature Time Step 
95 °C 2 min Initial denaturation 
95 °C 20 s 
20 Cycles 
55 °C 10 s 
70 °C 4 min 
70 °C 10 min Final extension 
4 °C ∞ Hold 
 
The template plasmid was isolated from a dam+ E. coli strain, so the original strands were 
suitable for DpnI digestion (see Table 10).  
As aggregated mKO2-TDP-43 constructs turned out to emit residual signal into the green 
channel, we needed to select a different fluorescent tag, which would allow us to visualize 
two fluorescent proteins at the same time. mTagBFP2 (Addgene #34632, deposited by 
Vladislav Verkhusha, (Subach et al. 2011)) turned out to be compatible with mCherry 
(Addgene #54631, deposited by Michael Davidson, (Kremers et al. 2009)). We cloned 
mTagBFP2TDP-43wt, mTagBFP2TDPdNLSd343 and mTagBFP2only into pcDNA5/FRT/TO 
using the following primers (Table 15): 
Table 15: Primer sequences used to amplify mTagBFP2 with PCR. 
Primer Name Sequence 
mTagBFP2 Fw GTTTAAACTTAAGCTGCCACCATGGTGTCTAAGGGCGAAGAGCT 
mTagBFP2Rev ATGTCGACTGCAGAATTCGAAGCTTGATTAAGCTTGTGCCCCAGTT 
BFP only rev AACGGGCCCTCTAGACTCGAGCTAATTAAGCTTGTGCCCCAGTT 
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Components of PCR-reaction mix and cycling conditions were similar to those in chapter 
4.1.1. Then plasmid pcDNA/FRT/TO was digested with HindIII (Thermo Fisher Scientific) 
and XhoI (Thermo Fisher Scientific) and mTagBFP2 was inserted into it by CloneEZ kit (see 
chapter 4.1.5) to produce pcDNA/FRT/TO-BFPonly plasmid. To get pcDNA/FRT/TO-BFP-
TDPwt and pcDNA/FRT/TO-BFP-TDPdNLSd343 plasmids, pcDNA/FRT/TO-mKO2-TDPwt 
and pcDNA/FRT/TO-mKO2-TDP-dNLSd343 were digested by OliI (Thermo Fisher Scientific) 
and HindIII (Thermo Fisher Scientific) and mTagBFP2 was inserted into them by CloneEZ kit 
(see 4.1.5). 
pmCherryC1-TDP-43wt was made similarly to pmKO2C1-TPD-43wt (see 4.1.1) and the 
amplified construct was inserted into pcDNA/FRT/TO by ClonEZ kit in a similar fashion as 
mKO2-TDP-43wt construct (see 4.1.5 and Table 16).  
Table 16: Primer sequences used to amplify mCherry-TDP-43wt from pmCherryC1-TDP-43wt. 
Primer Name Sequence 
mCherryFw CCC CGT AAT GCA GAA GAA GA 
TDPflRev AAA AGG ATC CCT ACA TTC CCC AGC CAG AAG 
 
4.1.7. Plasmids with Other ALS-Related Genes 
First, we prepared a parental pcDNA/FRT/TO-HRV 3C site-3xHA plasmid containing 
features, potentially useful for future cloning needs. To this end, we multiplied a fragment 
that was a part of a larger plasmid, previously ordered as a gBlock DNA fragment (IDT) 
containing HRV 3C site, Gly-Ser-Gly linker, 3x HA tag and some additional sequences. PCR 
was perfomed with Phusion HF Polymerase (Table 17).  
Table 17: Primer sequences used for PCR. 
Primer Name Sequence 
HRV 3C site Fw AGTGGCGGCCGCTCGAGGGAAGCGGCCTGGAAGTTCTGT 
Rev HRV 3xHA TCAGCGGGTTTAAACGGGCCCCTAAGCGTAATCTGGAACGTCGTA 
 
To perform CloneEZ reaction, plasmid pcDNA/FRT/TO was first digested with ApaI (NEB) 
for 1 h at 25 °C in CutSmart Buffer (NEB) and after with XhoI (NEB) in the same buffer at 37 
°C for 20 min. CloneEZ reaction was performed with the multiplied fragment and linearized 
plasmid according to manufacturer’s protocol (see 4.1.5). Reaction mixture was then 
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transformed into competent DH5α bacteria (see 4.1.4). Plasmids were isolated and their 
sequences tested by sequencing (Eurofins Genomics).  
Selected ALS-linked genes were ordered from Addgene (Table 18). 
Table 18: Plasmids containing ALS-linked genes ordered from Addgene. 
Plasmid name Addgene cat. no. Depositing lab 
VCP (wt)-EGFP 23971 Nico Dantuma (Tresse et al. 2010) 
p4455 FLAG-hPLIC-2 8661 Peter Howley (Kleijnen et al. 2000) 
FLAG-MATR3 32880 Yossi Shiloh (Salton et al. 2011) 
pET9d-hnRNP-A1 23026 Douglas Black (unpublished) 
 
Target genes were copied from received plasmids with PCR ( 
Table 2 and Table 19).  
Table 19: Primer sequences used for PCR. 
Primer Name Sequence 
Fw MATR3 3xHA GAATTCTGCAGATATCAGCCACCATGGCGTCCAAGTCATTCCAGCAG 
Rev MATR3 3xHA TCCAGGCCGCTTCCCTCGAGACATCCGCCAGTTTCCTTCTTCTGTCTG 
FwhnRNPA1 3xHA GAATTCTGCAGATATCAGCCACCATGGCGTCTAAGTCAGAGTCTCCTAA 
RevhnRNPA1 3xHA TCCAGGCCGCTTCCCTCGAGACATCCGCCAAATCTTCTGCCACTGCCA 
Fw VCP 3xHA TGGAATTCTGCAGATATCAGCCACCATGGCTTCTGGAGCCGATT 
Rev VCP 3xHA TCCAGGCCGCTTCCCTCGAGACATCCGCCGCCATACAGGTCATCATC 
Fw UBQLN2 3xHA ATTCTGCAGATATCAGCCACCATGGCTGAGAATGGCGAGA 
Rev UBQLN2 3xHA TCCAGGCCGCTTCCCTCGAGACATCCGCCCGATGGCTGGGAGCCCAG 
 
Multiplied genes were inserted into linearized plasmid pcDNA/FRT/TO-HRV 3C site-3xHA, 
previously digested with XhoI (Thermo Fisher Scientific) and EcoRV (Thermo Fisher 
Scientific), using CloneEZ kit (see 4.1.5). Reaction mixture was added to competent DH5α 
bacteria (see 4.1.4) and sequences of the isolated plasmids were confirmed by sequencing 
(Eurofins Genomics).  
To introduce ALS-linked mutation, site-directed mutagenesis was performed (Table 20).  
Table 20: Primer sequences used for site-directed mutagenesis. Sites of the nucleotide change are in small 
caps and underlined.  
Primer Name Sequence AA 
change 
Fw Matr3 C-G TTCTTCCCATAATTTGCAGTgTATATTTAACATTGGAAGT S85C 
Rev Matr3 C-G ACTTCCAATGTTAAATATAcACTGCAAATTATGGGAAGAA 
Fw hnRNPA1 A-T  GAGGTGGTGGAAGCTACAATGtTTTTGGGAATTACAACAATC D262V 
Rev hnRNPA1 A-T  GATTGTTGTAATTCCCAAAAaCATTGTAGCTTCCACCACCTC 
Fw VCP G-A  CGAAGGGGAGCCTATCAAACaAGAGGATGAGGAAGAGTCCT 
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Rev VCP G-A AGGACTCTTCCTCATCCTCTtGTTTGATAGGCTCCCCTTCG R191Q 
Fw UBQLN2 C-A  CATAGGCCCTATAGTCaCTTTTACCCCCATA P506T 
Rev UBQLN2 C-A  TATGGGGGTAAAAGtGACTATAGGGCCTATG 
 
Thermocycling reaction was performed with KOD Hot Start Polymerase (see Table 13 and 
Table 14) and template DNA was digested by DpnI enzyme (see Table 10).  
For control experiments, a plasmid containing 3xHA tag and additional 32 amino acid 
residues was prepared. Start codon was introduced into pcDNA5/FRT/TO-HRV 3C plasmid 
by site directed mutagenesis (Table 21). 
Table 21: Primer sequences for site directed mutagenesis. 
Primer Name Sequence 
Fw 3xHA Start GCTCGGATCCACTAGGCCACCATGTCCAGTGTGGTGG 
Rev 3xHA Start CCACCACACTGGACATGGTGGCCTAGTGGATCCGAGC 
 
Thermocycling reaction was performed with KOD Hot Start Polymerase (see Table 13 and 
Table 14) and template DNA was digested by DpnI enzyme (see Table 10). 
4.2. Cell Culture  
Neuroblastoma cells SH-SY5Y (ATCC® CRL-2266™) were cultured as a monolayer in 75 cm2 
flasks in DMEM/F-12 (Thermo Fisher Scientific), supplemented with 10 % (v/v) FBS 
(Thermo Fisher Scientific) and penicillin-streptomycin solution (Thermo Fisher Scientific) at 
37 °C in a humidified atmosphere containing 5 % CO2. When they reached confluency, they 
were washed with PBS (Thermo Fisher Scientific), trypsinized by TrypLE Select (Thermo 
Fisher Scientific) and replated. SH-SY5Y cell line was used between passages 19 and 30, and 
then the cells were discarded. 
hTERT RPE-1 cell line (ATCC® CRL-4000™) are retinal epithelial cells immortalized with 
hTERT. They were cultured as a monolayer in 75 cm2 flasks in DMEM (Thermo Fisher 
Scientific), supplemented with 10 % (v/v) FBS (Thermo Fisher Scientific) and penicillin-
streptomycin solution (Thermo Fisher Scientific) at 37 °C in a humidified atmosphere 
containing 5 % CO2. They were subcultured twice a week in a 1:10 ratio.  
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4.2.1. Transfection 
For experiments that required transfection, Xfect Transfection Reagent (Takara Bio) was 
used. For immunocytochemistry, 1.1x105 SH-SY5Y cells/well were plated on 12 mm 
coverslips into 24-well plates 24 h before transfection. For western blot analysis, 2.2 x105 
SH-SY5Y cells/well were plated into 12-well plates and 6.5x105 SH-SY5Y cells/well were 
plated on 6-well plates 24 h before transfection. For immunocytochemistry of RPE-1-TDP-
43mRuby2, 2.4x104 cells were plated on 12 mm coverslips into 24-well plates 24 h before 
transfection. For supernatant experiments, 5.0x105 RPE-1/TR cells were plated on 6 cm dish. 
For co-culture experiments, 9.0x105 RPE-1/TR cells were plated on 10 cm dish 24 h before 
transfection. Cells were transiently transfected using Xfect transfection reagent according to 
manufacturer instructions: 
 Cells had to be 50 – 70% confluent at the time of transfection. 
 First, growth medium had to be replaced just prior to transfection. 
 Then, Xfect Polymer had to be thoroughly vortexed. 
 DNA had to be diluted in Xfect Reaction Buffer prior to adding Xfect Polymer. 
 Ratio of Polymer:DNA was always the same; 0.3 µL Xfect Polymer per 1 µg of plasmid 
DNA. 
 Co-transfection experiments were carried out with plasmids DNA in ratios 1:1. 
Transfections were performed with 1 µg total DNA/well for 24-well plates, 2.5 µg total 
DNA/well for 12-well plates, 7.5 µg total DNA/well for 6-well plates, 15 µg total 
DNA/well for 6 cm dishes and 35 µg total DNA/well for 10 cm dishes. 
 After Xfect Polymer was added to the diluted plasmid DNA, the solution had to be 
vortexed for 10 s. 
 The solution was then incubated for 10 min at room temperature to allow 
nanoparticle complexes to form. 
 The nanoparticle complex solution was then added dropwise to the culture medium. 
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 The cells were incubated for 4 h with the Xfect-DNA nanoparticles and then the 
growth media was replaced with fresh warm media. 
 All of the co-transfections were carried out side-by-side at the same time to allow 
comparisons between different experimental conditions. 
4.2.2. Generation of SH-SY5Y FlpIn Cell Line 
A pcDNA6/TR vector (Thermo Fisher Scientific) was introduced into SH-SY5Y cells for high-
level expression of the tetracycline repressor protein. pcDNA6/TR vector was linearized with 
FspI restriction enzyme (NEB), purified with PCR Clean-up (Macherey-Nagel) and used for 
transfection of SH-SY5Y cells using Xfect transfection reagent (Takara Bio) according to 
manufacturer’s instructions. Upon 48 h, cells were exposed to the selection medium 
containing tetracycline free FBS (Gibco) and Blasticidine S at 5 µg/mL (Sigma Aldrich). Single 
cell cloning of resistant cells was performed by single cell sorting to achieve homogenous 
expression of the repressor protein. To test the efficiency of repression, cells from individual 
colonies were transfected with a plasmid containing eGFP under a Tet operator. As resulting 
SH-SY5Y-TR-eGFP cells exhibited no residual eGFP expression in tetracycline free medium, 
yet upon addition of 1 µg/mL of Doxycycline (Sigma Aldrich) they produced high levels of 
fluorescent protein, the original SH-SY5Y-TR cells were chosen for FlpIn SH-SY5Y-TR-FRT 
cell line development. To introduce FRT recombination site into the cells, pFRT/lacZeo 
(Thermo Fisher Scientific) was linearized with ApaI (NEB) restriction enzyme, purified with 
PCR Clean-up and transfected into SH-SY5Y-TR cells (Xfect, Takara Bio). Forty-eight hours 
later cells were subjected to selection medium containing tetracycline free (Tet-free) FBS and 
300 µg/mL Zeocin (Thermo Fisher Scientific). They were single cell cloned via single cell 
sorting. Clones of SH-SY5Y-TR-FRT cells were expanded for Southern blot analysis to verify 
that they harbor only one recombination site. FlpIn SH-SY5Y-TR-FRT cells containing a single 
FRT insertion site were used for generation of inducible SH-SY5Y-TR-FRT-mCherryTDP-
43wt cell line. SH-SY5Y-TR-FRT cells were co-transfected with pcDNA5-FRT-TO-
mCherryTDP-43wt and pOG44 vectors at 1:9 ratio and stable SH-SY5Y-TR-FRT-
mCherryTDP-43wt cell line was established by hygromycin (110 µg/µL) selection. 
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4.2.3. Generation of RPE-1/TR Cell Line 
A pcDNA6/TR vector (Thermo Fisher Scientific) was introduced into RPE-1 cells for high-
level expression of the tetracycline repressor protein. pcDNA6/TR vector was linearized with 
FspI restriction enzyme (NEB), purified with PCR Clean-up (Macherey-Nagel) and used for 
transfection of RPE-1 cells using Xfect transfection reagent (Takara Bio) according to 
manufacturer’s instructions. Upon 48 h, cells were exposed to selection medium containing 
tetracycline free FBS (Gibco) and Blasticidine S at 15 µg/mL (Sigma Aldrich). Single cell 
cloning of resistant cells was performed by single cell sorting to achieve homogenous 
expression of repressor protein. To test the efficiency of repression, cells from individual 
colonies were transfected with a plasmid containing eGFP under a Tet operator. As resulting 
RPE-1/TR-eGFP cells exhibited no residual eGFP expression in tetracycline free medium, yet 
upon addition of 1 µg/mL of Doxycycline (Sigma Aldrich) they produced high levels of 
fluorescent protein, they were selected for subsequent experiments. 
4.2.4. Transfection and Induction of SH-SY5Y-TR-FRT-mCherryTDP-43wt Cell 
Line 
SH-SY5Y-TR-FRT-mCherryTDP-43wt cell line was grown in Tet-free growing media. 1.1x105 
cells/well were plated on 12 mm coverslips into 24-well plates 24 h before transfection. Cells 
were transfected with Xfect Transfection Reagent (Takara Bio) (see 4.2.1) and 4 h after 
transfection, the media was replaced with media containing 1 µg/mL of Doxycycline. Twenty-
four hours after transfection, the cells were fixed with 4 % PFA (see 4.5).   
4.2.5. Transfection and Induction of RPE-1-TDP-43mRuby2 Cell Line 
RPE-1-TDP-43mRuby2 cell line was generated by post doc in Cleveland lab, Haiyang Yu and 
it constitutively expresses wild-type TDP-43 tagged with Myc-tag at its N-terminus and 
mRuby2 at its C-terminus. 2.4x104 cells were plated on 12 mm coverslips into 24-well plates 
24 h before transfection. Cells were transfected with Xfect Transfection Reagent (Takara Bio) 
(see 4.2.1) and 4 h after transfection, the media was replaced with media containing 3.5 µM 
Palbociclib (Selleck Chemicals) to arrest them in G1 cell cycle phase, so they would stop 
dividing. Cells were fixed with 4 % PFA either after 24 h or at a later time point (see 4.5).   
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4.2.6. Co-culture Experiment 
First, 9.0x105 RPE-1/TR cells were seeded on 3x 10 cm dishes in Tet-free media. The next 
day, cells were transfected with BFP-TDPwt, BFP-TDPdNLSd343 or BFPonly they were still 
kept in Tet-free media. Twenty-four hours after transfection, cells were trypsinized and 
1.6x104 transfected cells were plated together with 8.0x103 RPE-1-TDP-43mRuby2 cells on 
12 mm coverslips into 24-well plates in media containing 1 µg/mL of Doxycycline (Sigma 
Aldrich) and 3.5 µM Palbociclib (Selleck Chemicals). Cells were fixed with 4 % PFA either 
after 24 h or at later time points (see 4.5).   
4.2.7. Supernatant Experiment 
First, 5.0x105 RPE-1/TR cells were plated in Tet-free media on 2x 6 cm dishes for each 
construct, 6 dishes in total. The next day, cells were transfected with BFP-TDPwt, BFP-
TDPdNLSd343 or BFPonly and when changing the media, 3.5 µM Palbociclib (Selleck 
Chemicals) to prevent the dilution of the transfected cells and 1 µg/mL of Doxycycline (Sigma 
Aldrich) were added to the cells. Forty-eight hours after transfection, 2.4x104 RPE-1-TDP-
43mRuby2 cells were plated on 12 mm coverslips into 24-well plates in media containing 
and 3.5 µM Palbociclib (Selleck Chemicals). The next day, 200 µL of the media from 
transfected cells was transferred to RPE-1-TDP-43mRuby2 cells. This was repeated every 
third day, together with additional supplement of Palbociclib to compensate for the decayed 
compound. Cells were fixed with 4 % PFA either after 24 h or at later time points (see 4.5).   
4.3. Cell Lysates 
4.3.1. Total Cell Lysates 
For total cell lysates, 24 h after transfection SHSY5Y cells in 12-well plates were washed 3x 
with ice-cold PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4) and 
lysed in 60 µL 2x SDS loading buffer (100 mM Tris-Cl (pH 6.8), 4% (w/v) SDS, 0.2% (w/v) 
bromophenol blue) with 0.1 M DTT. The cells were scraped from the growing surface with a 
clean and sterile pipette tip and transferred into a chilled 1.5 mL Eppendorf tube. Samples 
were boiled at 100 °C for 10 min.  
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4.3.2. RIPA-Soluble Fraction 
For RIPA-soluble fraction, SH-SY5Y cells in 6-well plates were washed 3x with ice-cold PBS 
and lysed in 200 µL RIPA buffer (50 mM Tris pH 8.0, 150 mM NaCl, 1% NP-40, 5 mM EDTA, 
0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS) containing protease 
inhibitors (cOmplete ULTRA tablets mini, EDTA-free EASYpack, Roche) and phosphatase 
inhibitors (PhosSTOP EASYpack, Roche)). The cells were scraped from the growing surface 
with a clean and sterile pipette tip and transferred into a chilled 1.5 mL Eppendorf tube. 
Samples were sonicated using an ultrasonic probe (cycle 0.5, amplitude 80%, 3x 15 s interval 
– samples were cooled on ice during the intervals) and centrifuged at 21,000 × g for 30 min 
at 4 °C. The supernatants were saved for analysis as RIPA-soluble fraction, 6x SDS loading 
buffer with 0.3 M DTT was added to them and they were boiled at 100 °C for 10 min. 
4.3.3. UREA-Soluble Fraction 
 The residual pellets were washed 3x in 200 µL RIPA buffer and centrifuged at 21,000 × g for 
30 min at 4 °C each time. After the last wash, 20 µL of UREA buffer (7 M urea, 2 M thiourea, 
4% CHAPS, and 30 mM Tris, pH 8.5) was added to the pellets. The pellets were resuspended 
by pipetting and centrifuged again at 21,000 × g for 30 min at 22 °C. The supernatants were 
collected as UREA-soluble fraction and 6x SDS loading buffer with 0.3 M DTT was added to 
them. 
4.4. Protein Detection 
4.4.1. Polyacrylamide Gel Electrophoresis 
Samples with added SDS loading buffer were loaded to Novex WedgeWell 8 - 16 % Tris-
Glycine gels with 15 wells (Invitrogen Thermo Fisher Scientific):10 µL of total lysates, 10 µL 
of RIPA-soluble fraction and 15 µL of UREA-soluble fraction. To assess sizes of protein 
samples, PageRuler Plus (Fermentas) was loaded to the gels too. Samples were run in SDS 
running buffer (25 mM Tris, 192 mM glycine, 0.1 % SDS) at 120 V for 90 min.  
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4.4.2. Western Transfer 
Proteins were transferred onto Trans-Blot Turbo 7.1 cm x 8.5 cm mini-size nitrocellulose 
membrane (Bio-Rad) by Trans-blot turbo transfer system (Bio-Rad) in Trans-blot turbo 
Transfer buffer (Bio-Rad) with 20 % EtOH. Settings: 1 mini gel, Program: High MW, time: 13 
min. 
4.4.3. Protein Detection with Antibodies  
Membranes were first washed once in TBS (50 mM Tris, pH 7,5; 150 mM NaCl), blocked in 5 
% skim milk in TBST (TBS with 0.1 % Tween) for 30 min and then incubated overnight with 
primary antibodies in 5 % skim milk in TBST (rabbit polyclonal anti-TDP-43 1:3000, #10782-
2-AP Proteintech; mouse anti-HA 1:5000, #HA-7 Sigma; mouse anti-GAPDH 1:5000, #60004-
1-Ig Proteintech; rabbit polyclonal anti-GAPDH 1:5000, #10494-1-AP Proteintech). The next 
day, membranes were washed 3x in TBST and incubated with secondary antibodies in 5 % 
skim milk in TBST for 1.5 h (anti-Rabbit Alexa 488 Cell Signaling Molecular Probes; anti-
Mouse Alexa 647 Cell Signaling Molecular Probes; anti-Rabbit Alexa 647 Cell Signaling 
Molecular Probes; anti-Mouse Alexa 488 Cell Signaling Molecular Probes, all 1:5000). Upon 
three washes in TBST, the fluorescence signal was detected using Chemidoc BioRad Imaging 
System (Bio-Rad).    
4.5. Immunocytochemistry 
Twenty-four hours after transfection, cells were washed 3x with PBS, fixed in 4 % PFA 
(Electron Microscopy Processing) in PBS for 30 min and washed with PBS again. Then they 
were permeabilized with 0.1 % TX-100 for 10 min, blocked in 3 % BSA (bovine serum 
albumin) in PBS for 30 min and incubated with primary antibodies (rabbit polyclonal anti-
HA-tag (C29F4) Cell Signaling, #3724, 1:500; mouse monoclonal anti-Lamp2 BD, #558758, 
1:500; mouse monoclonal anti-Myc (C-Myc: 9E10) Sigma, #M5546, 1:500; rabbit polyclonal 
anti-TDP Proteintech, #10782-2-AP, 1:500) overnight at 4 °C. The next day, the coverslips 
were washed, incubated with secondary antibodies (anti Rb_Alexa647 #4414 1:1000; Cell 
Signaling, anti Ms_AlexaFITC, Jackson ImmunoResearch #715-095-151, 1:1000) for 2 h, 
incubated in DAPI solution (0.1 µg/mL) (Thermo Fisher Scientific) for 15 min or for co-
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culture experiments with DRAQ5 solution (10 µM) (Thermo Fisher Scientific) for 20 min and 
mounted on microscope slides with ProLong™ Gold Antifade Mountant (Thermo Fisher 
Scientific).  
4.6. Imaging and Statistical Analysis 
Slides were analyzed by confocal microscopy (Zeiss LSM 710Z) using ZEN software. 
Fluorescence was excited by three lasers with different wavelengths: 405 nm, 543 nm and 
633 nm. Each of the channels was acquired separately to avoid interference of the signals. 
The acquired images had 1024 x 1024 pixels and 12-bit.   
Three experiments were performed in duplicates for each experimental condition and a 
minimum of 15 visual fields, each containing between 50 and 70 cells from each duplicate 
were taken. Overall, between 550 and 3400 transfected cells were analyzed per each 
experimental condition. Percentage of transfected cells harboring TDP-43 aggregates was 
quantified by manual counting.  
4.6.1. Image Analysis by ImageJ Shape Descriptors Plugin  
Further analysis of number of aggregates per cell and their size were performed with ImageJ 
Shape Descriptors plugin (Figure 6) (Threshold: min. 164, max 255; Size: 3 - infinity; 
Circularity: 0.00 - 1.00). All data was recorded as averages ± SEM. The difference between 
averages was tested by Ordinary one-way ANOVA followed by Tukey multiple comparisons 
test using GraphPad Prism 6. The p-value <0.05 was considered statistically significant. 
*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 
 
65 
 
 
Figure 6: Shape Descriptors plugin. A) An input image. B) Image with applied threshold values. C) Freehand 
selection tool to outline aggregates in target cell. D) Menu to determine Shape Descriptor values. E) Outlined 
particles determined by Shape Description plugin. F) Result table.    
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5. Results 
5.1. TDP-43 Aggregation is Affected by Shortening of the C-terminal Domain 
5.1.1. Western Blot Analysis of TDP-43 Constructs Transfected in SH-SY5Y 
Cells 
To test the effect of C-terminal domain on TDP-43 aggregation, SH-SY5Y cells were 
transfected with various mKO2 tagged TDP-43 constructs lacking NLS (dNLS) and different 
parts of LCD (dNLSd343, dNLSd299, and dNLSd267) – see Figure 7A. Wild-type TDP (TDPwt) 
was used to compare to the baseline aggregate formation of the wild-type TDP-43 protein 
and fluorescent protein mKO2 alone (KO2only) was used as a control for the effect of the 
fusion protein on aggregation (Figure 7A). The expression of all constructs was detected with 
anti-TDP-43 antibody on western blot at predicted sizes (Figure 7B). 
 
Figure 7: Western blot analysis of TDP-43 constructs with C-terminal domain truncations transfected 
into SH-SY5Y cells.  (A) A schematic representation of mKO2-tagged constructs and their abbreviations. Only 
TDPwt has NLS, whereas others lack NLS and except dNLS that holds intact C-terminus, they carry deletions of 
LCD and have shortened length: IDR2 is deleted in dNLSd343 (ends at 343 aa residue), IDR2 and CR are deleted 
in dNLSd299 (ends at 299 aa residue), whole C-terminal domain is deleted in dNLSd267 (ends in 267 aa 
residues). A control construct KO2only holds sequence for mKO2 protein alone. (B) Western blot analysis of 
mKO2-tagged constructs. 
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5.1.2. C-terminal Domain Truncations Affect TDP-43 Aggregate Formation 
As expected, elimination of NLS in TDP-43 led to an increased percentage of cells with 
cytoplasmic aggregation of dNLS (24.4 ± 0.80 %) compared to wild-type TDP-43 protein (3.8 
± 0.80 %) (Figure 8A). Moreover, a deletion of intrinsically disordered region 2 (IDR2) at the 
extreme C-terminus of TDP-43 (dNLSd343) resulted in even higher percentage of transfected 
cells harboring dNLSd343 aggregates (33.0 ± 0.20 %). Contrary, transfection of cells with 
constructs carrying C-terminal deletions of CR (dNLSd299) or IDR1 (dNLSd267) of TDP-43, 
decreased the percentage of cells with dNLSd299 (6.9 ± 0.57 %) and dNLSd267 (4.1 ± 1.37 
%) aggregates. Further aggregate analyses within each individual cell revealed that 
expression of dNLS resulted in the highest number of cytoplasmic aggregates per individual 
cell (14.1 ± 0.80) compared to the expression of any other TDP-43 truncated form (Figure 
8B). However, the largest aggregates in size were noted in cells expressing dNLSd343 (4.2 ± 
0.36 µm2) and dNLS299 (4.8 ± 0.61 µm2) constructs (Figure 8C and D). Altogether, this is 
implying that aside the lack of NLS, which is enabling cytoplasmic mislocalization of TDP-43, 
the elimination of specific regions of TDP-43 LCD may interfere with different stages of 
aggregate formation, either their initiation (aggregation proneness) or aggregation 
maturation. 
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Figure 8: C-terminal domain truncations affect TDP-43 aggregate formation in the cytoplasm of SH-SY5Y 
cells.  (A) Quantification of transfected cells harboring aggregates. (B) Average number of aggregates in an 
individual cell. (C) Average aggregate size within individual cells. (D) SH-SY5Y cells, expressing mKO2-tagged 
constructs. Nuclei are counterstained with DAPI. Scale bars: 10 µm. 
5.1.3. Despite Lacking the Extreme C-terminus, TDPdNLSd343 Sequesters 
Wild-Type TDP-43 from the Nucleus 
Before conducting any further experiments, we wanted to test whether TDPdNLSd343 
inclusions despite lacking the extreme C-terminus have similar ability as TDP-43 C-terminal 
fragments (Che et al. 2015; Nonaka et al. 2009) to sequester wild-type TDP-43 from the 
nucleus. As mKO2-TDP-43 aggregates proved to emit fluorescence into the green channel 
(488 nm), we have selected a fluorescent protein mTagBFP to add to TDP-43 constructs that 
turned out to be compatible with mCherry and the pair allowed us to monitor two proteins 
with fluorescent tags at the same time. mCherry-TDP-43wt was inserted into SH-SY5Y-TR-
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FRT cell line and upon transfection with BFP-TDP-43 constructs, doxycycline was added to 
the Tet-free media to allow the production of the proteins. While BFP-TDPwt and BFPonly 
did not change nuclear localization of mCherry-TDP-43wt (Figure 9), BFP-TDPdNLSd343 
sequestered mCherry-TDP-43wt into cytoplasmic aggregates (see arrows on Figure 9). 
 
Figure 9: BFP-TDP-43dNLSd343 sequesters inducibly expressed mCherry-TDP-43wt from the nucleus. 
SH-SY5Y-TR-FRT-mCherryTDP-43wt cell line transfected with BFP-TDPwt, BFP-TDP-43dNLSd343 or BFPonly. 
Scale bars: 10 µm. 
To test, whether the sequestration of mCherryTDP-43wt from the nucleus was cell-type 
dependent, we performed a similar experiment using RPE-1-TDP-43mRuby2 cell line, 
developed by Haiyang Yu, a post doc from Cleveland Lab. RPE-1-TDP-43mRuby2 cell line 
constitutively expresses TDP-43 tagged with mRuby2 and does not express Tet repressor, 
therefore following transfection with BFP-TDPwt, BFP-TDPdNLSd343, or BFPonly no 
addition of doxycycline was needed. As in SH-SY5Y cells, BFP-TDPwt and BFPonly did not 
change nuclear localization of TDP-43mRuby2, while BFP-TDPdNLSd343 sequestered TDP-
43mRuby2 into cytoplasmic inclusions (Figure 10). Presence of TDP-43 in the inclusions was 
confirmed by detection with anti-TDP-43 antibody. 
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Figure 10: BFP-TDP-43dNLSd343 sequesters constitutively expressed TDP-43mRuby2 from the 
nucleus. RPE-1-TDP-43mRuby2 cell line transfected with BFP-TDPwt, BFP-TDP-43dNLSd343 or BFPonly. Scale 
bars: 50 µm. 
5.1.4. TDPdNLSd343 Aggregates Spread Among Cells in Culture, but They do 
not Initiate Widespread Aggregation in the Recipient Cells  
To study whether TDPdNLSd343 aggregates spread from cell to cell, we designed a co-culture 
experiment with two compatible fluorescently tagged TDP-43 constructs (Figure 11). We 
selected RPE-1 cells over SH-SY5Y cell line due to their high transfection efficiency as any 
non-transfected cells in co-culture would dilute our efforts to monitor spreading of the 
aggregates to the neighboring cells. Palbociclib was added to the cells to arrest their cell cycle 
in G1 phase, so the cell division would not dilute the aggregates and aggregation processes. 
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Figure 11: Experimental design for studying intercellular spreading of TDP-43 aggregates in co-cultured 
cells. 
As seen in Figure 12, BFP-TDPdNLSd343 aggregates are able transfer from the transfected 
cells into cells expressing TDP-43mRuby2 (Figure 12A). The ratio of cells harboring both, 
mRuby2 and mTagBFP2 fluorescence signal in comparison to cells with only one 
fluorescence signal has gradually increased over time (Figure 12B). However, even 
prolonged co-culture has failed to induce widespread spreading of aggregation in the 
recipient cells, indicating that the received aggregates do not come easily into contact with 
the wild-type TDP-43.  
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Figure 12: BFP-TDPdNLSd343 aggregates transfer from transfected RPE-1/TR cells into neighboring 
RPE-1 cells expressing TDP-43mRuby2.  A) Cells growing in co-culture for 3, 6 or 10 days. Scale bars: 50 µm. 
B) Quantification of cells with a single fluorescent signal or with double fluorescent signal following different 
co-culture time points.  
To see, whether the mode of exposure to the aggregates influences aggregation processes in 
recipient cells, we designed an experiment, where recipient cells were exposed to the 
supernatant previously incubated for 48 h with the transfected cells (Figure 13). Palbociclib 
was added to the cells to arrest their cell cycle in G1 phase, so the cell division would not 
dilute the aggregates and aggregation processes.  
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Figure 13: Experimental design for studying spreading of TDP-43 aggregates from the supernatant 
collected from transfected cells into recipient cells. 
Incubation of the supernatant of RPE-1 cells transfected with BFP-TDPdNLSd343, led to the 
uptake of the aggregates into the recipient cells constitutively expressing TDP-43mRuby2 
(Figure 14A). While there was some translocation of TDP-43mRuby2 from the nucleus into 
cytoplasmic aggregates, the received aggregates did not succeed in initiating widespread 
aggregation in the cultured cells. On the contrary, the percentage of cells displaying BFP 
signal gradually declined (Figure 14B), indicating their degradation and elimination from the 
culture.  
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Figure 14: TDP-43dNLSd343 aggregates are transferred from the supernatant of transfected cells into 
recipient cells.  A) BFP-TDPdNLSd343 aggregates can be detected in the cytoplasm of the recipient cells. Scale 
bars: 50 µm. B) Quantification of the recipient cells containing BFP signal following different time points. 
The inability of BFP-TDPdNLSd343 aggregates to induce aggregation in the recipient cells 
and their elimination from the culture prompted us to compare lysosomal marker Lamp2 in 
RPE-1/TR cells transfected with TDPdNLSd343 construct with RPE-1/TDP-43mRuby2 cells 
exposed to TDPdNLSd343 aggregates. As seen in Figure 15, TDPdNLSd343 aggregates 
expressed in RPE-1/TR cells after transfection were not Lamp2-positive, indicating that they 
are not located in a lysosomal vesicle. In contrast, TDPdNLSd343 aggregates, uptaken from 
the supernatant by RPE-1/TDP-43mRuby cells are Lamp2-positive, suggesting that a 
membrane enveloping the aggregates prevents them to sequester TDP-43mRuby2 from the 
nucleus and since they are positive for lysosomal markers, they eventually get degraded.  
 
Figure 15: Comparison of lysosome marker Lamp2 in RPE-1/TR cells transfected with KO2-
TDPdNLSd343 and RPE-1 TDP-43mRuby2 cells incubated with supernatant from RPE-1/TR cells 
transfected with BFP-TDPdNLSd343. 
5.2. The Mutations of ALS-Associated Genes Display an Impact on TDP-43 
Aggregation Behavior 
The expression of both dNLS and dNLSd343 resulted in highly increased percentage of cells 
exhibiting cytoplasmic aggregates; however, they clearly displayed distinct number and size 
per individual cell (compare Figure 8B, C and D). Therefore, we decided to employ both of 
these TDP-43 aggregation models for further testing the effects of wild-type and mutated 
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ALS-linked genes on their aggregation profile. For this reason, we co-transfected the SH-SY5Y 
cells with either TDPwt, dNLS, dNLSd343 or KO2only with selected wild-type (wt) or mutant 
(mut) ALS-linked gene tagged with 3xHA: hnRNPA1, MATR3, VCP or UBQLN2. These genes 
were selected based on their diverse roles in RNA processing and quality control of protein 
metabolism. A plasmid containing 3xHA with additional 96-nucleotide sequence 
(pcDNA5/FRT/TO/3xHA - HAonly) was used as a baseline control of the aggregate formation 
(Figure 16). 
 
Figure 16: TDP-43 constructs co-transfected with plasmid HAonly.  (A) Quantification of co-transfected 
cells harboring aggregates. (B) Average number of aggregates in individual cells. (C) Average aggregate size. (D) 
SH-SY5Y cells co-transfected with mKO2-TDP-43 constructs and HAonly plasmid. Probed for HA-tag and 
counterstained with DAPI. Scale bars: 10 µm.  
The solubility of the aggregates following co-transfection of TDPdNLS and TDPdNLSd343 
with HAonly was analyzed by separation of RIPA- and UREA-soluble fractions (Figure 17). 
RIPA buffer releases proteins from cells and disrupts most weak interactions between 
proteins. Proteins, insoluble in RIPA fraction where subsequently subjected to UREA buffer. 
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Chaotropic compounds such as urea disrupt hydrogen bonds and hydrophobic interactions 
both between and within proteins. In high concentrations, they destroy secondary protein 
structure and bring otherwise insoluble proteins into solution. TDPdNLS was more enriched 
in UREA-soluble fraction in comparison to TDPdNLSd343; however, this could be also a 
consequence of TDPdNLSd343 lower expression levels. 
 
 
Figure 17: Solubility of TDPdNLS and TDPdNLSd343 constructs co-transfected with HA-only plasmid. 
RIPA-soluble and UREA-soluble fractions of SH-SY5Y cells co-transfected with plasmid containing only 3xHAtag 
and TDPdNLS or dNLSd343. 
5.2.1. Overexpression of hnRNPA1 and Its D262V Mutation Inhibits TDP-43 
Aggregate Formation and Their Maturation 
The co-expression of wt and mut hnRNPA1 with KO2-tagged TDP-43 constructs in SH-SY5Y 
cells was confirmed by western blot analysis of total lysates of the co-transfected cells (Figure 
18). Similar to transfections with KO2-tagged TDP-43 constructs only, expression levels of 
TDPdNLSd343 were the lowest among the TDP-43 constructs.  
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Figure 18: Total lysates of cells co-transfected with wt or mut hnRNPA1 and TDP-43 constructs.  Western 
blot of total lysates of SH-SY5Y cells co-transfected with wt or mut HA-tagged hnRNPA1 and TDPwt, dNLS, 
dNLSd343, or KO2only, probed for HA-tag, TDP-43 and GAPDH as loading control. 
The co-transfection of dNLS and dNLSd343 constructs with either hnRNPA1wt or 
hnRNPA1mut resulted in a significantly lower percentage of transfected cells harboring 
aggregates. Though no difference in the percentage of cells harboring aggregates was noted 
between hnRNPA1wt (10.5 ± 1.77 %) and hnRNPA1mut (14.7 ± 1.72 %) co-transfected with 
dNLS, a co-transfection of hnRNPA1mut (14.6 ± 0.78 %) with dNLSd343 led to an increased 
percentage of cells with aggregates as compared to hnRNPA1wt (8.5 ± 1.02 %) co-
transfection (Figure 19A). Additionally, the number of aggregates more than halved in the 
cells co-transfected either with hnRNPA1wt (4.9 ± 0.69) or hnRNPA1mut (5.4 ± 0.80) and 
dNLS, as compared to cells co-transfected with control plasmid HAonly (13.1 ± 1.82) (Figure 
19B). Moreover, co-transfection of dNLS and dNLSd343 with hnRNPA1wt resulted in greatly 
decreased size of dNLS (0.7 ± 0.34 µm2) and dNLSd343 (1.2 ± 0.14 µm2) aggregates in 
comparison with the cells co-transfected with control HAonly (dNLS (2.1 ± 0.34 µm2) and 
dNLSd343 (3.9 ± 0.39 µm2)). The decreased aggregate size appeared more pronounced in 
case of dNLSd343 than dNLS cells co-transfected with either wild-type or mutant hnRNPA1 
(Figure 19C, D). The resulting aggregates in all co-transfected cells were similar in size. This 
suggests that IDR1 and CR domains of TDP-43 suffice for intermolecular interactions with 
hnRNPA1, which may play part in the inhibition of TDP-43 aggregate formation and 
maturation.  
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Figure 19: SH-SY5Y cells co-transfected with mKO2 constructs and wt or mut hnRNPA1.  (A) 
Quantification of co-transfected cells harboring aggregates. (B) Average number of aggregates in an individual 
cell. (C) Average aggregate size. (D) SH-SY5Y cells co-transfected with mKO2 constructs and wt or mut 
hnRNPA1. Probed for HA-tag and counterstained with DAPI. Scale bars: 10 µm. 
The insolubility of the aggregates following co-transfection of TDPdNLS and TDPdNLSd343 
with wt or mut hnRNPA1 was analyzed by separation of RIPA- and UREA-soluble fractions 
(Figure 20). Only the co-transfection of TDPdNLS and hnRNPA1mut produced some insoluble 
aggregates, proved by dNLS detection in UREA-soluble fraction with Western blot.   
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Figure 20: Solubility of TDPdNLS and TDPdNLSd343 constructs co-transfected with HA-tagged wt or mut 
hnRNPA1. . RIPA-soluble and UREA-soluble fractions of SH-SY5Y cells co-transfected with plasmids containing 
HA-tagged wt or mut hnRNPA1 and TDPdNLS or dNLSd343. 
 
5.2.2. MATR3 S85C Mutation Promotes TDP-43 Aggregation 
The co-expression of wt and mut MATR3 with KO2-tagged TDP-43 constructs in SH-SY5Y 
cells was confirmed by western blot analysis of total lysates of the co-transfected cells (Figure 
21). As in co-transfections with hnRNPA1 and KO2-tagged TDP-43 constructs, expression 
levels of TDPdNLSd343 were the lowest among the TDP-43 constructs. 
 
 
Figure 21: Total lysates of cells co-transfected with wt or mut MATR3 and TDP-43 constructs.  Western 
blot of total lysates of SH-SY5Y cells co-transfected with wt or mut HA-tagged MATR3 and TDPwt, dNLS, 
dNLSd343, or KO2only, probed for HA-tag, TDP-43 and GAPDH as loading control. 
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Co-transfection of either dNLS or dNLSd343 with MATR3wt had no effect on the percentage 
of cells with dNLS (24.9 ± 1.34 %) or dNLSd343 (26.5 ± 0.10 %) aggregates. On the other 
hand, MATR3mut co-transfected with either dNLS or dNLSd343 significantly increased the 
percentage of cells harboring both dNLS (36.9 ± 0.75 %) and dNLSd343 (32.3 ± 1.02 %) 
aggregates (Figure 22A). However, while neither MATR3wt nor MATR3mut displayed an 
effect on the number of aggregates within an individual cell (Figure 22B), both MATR3wt (5.1 
± 0.26 µm2) and MATR3mut (3.7 ± 0.30 µm2) evidently increased the size of aggregates in 
cells co-transfected with dNLS (Figure 22C, D). These results are implying that even though 
MATR3wt does not seem to promote aggregate formation to the extent that its mutated form 
does, it nonetheless similarly promotes TDP-43 dNLS aggregate maturation, irrespective of 
TDP-43 C-terminal truncations. 
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Figure 22: SH-SY5Y cells co-transfected with mKO2 constructs and wt or mut MATR3.  (A) Quantification 
of co-transfected cells harboring aggregates. (B) Average number of aggregates in an individual cell. (C) Average 
aggregate size. (D) SH-SY5Y cells co-transfected with mKO2 constructs and wt or mut MATR3. Probed for HA-
tag and counterstained with DAPI. Scale bars: 10 µm. 
The increased size of dNLS aggregates co-expressed with MATR3 was also confirmed by the 
detection of dNLS in UREA-soluble fraction with western blot, demonstrating that the co-
transfection of MATR3wt and dNLS produces more insoluble aggregates than the co-
transfection of dNLS with MATR3mut in the cells (Figure 23). 
82 
 
 
Figure 23: Solubility of TDPdNLS and TDPdNLSd343 constructs co-transfected with HA-tagged wt or mut 
MATR3. RIPA-soluble and UREA-soluble fractions of SH-SY5Y cells co-transfected with plasmids containing HA-
tagged wt or mut MATR3 and TDPdNLS or dNLSd343. 
 
5.2.3. VCP R191Q Mutation Promotes TDP-43 dNLS but not dNLS343 
Aggregate Maturation 
The co-expression of wt and mut VCP with KO2-tagged TDP-43 constructs in SH-SY5Y cells 
was confirmed by western blot analysis of total lysates of the co-transfected cells (Figure 24). 
The expression levels of TDPdNLSd343 were the lowest among the TDP-43 constructs. 
 
Figure 24: Total lysates of cells co-transfected with wt or mut VCP and TDP-43 constructs.  Western blot 
of total lysates of SH-SY5Y cells co-transfected with wt or mut HA-tagged VCP and TDPwt, dNLS, dNLSd343, or 
KO2only, probed for HA-tag, TDP-43 and GAPDH as loading control. 
The co-transfection of dNLS or dNLSd343 with VCPmut resulted in significantly increased 
percentage of cells harboring dNLS (39.7 ± 0.36 %) and dNLSd343 (32.3 ± 1.97 %) aggregates 
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in comparison with the cells co-transfected with VCPwt (dNLS (30.1 ± 1.04 %) and dNLSd343 
(23.1 ± 0.95 %)) or control plasmid HAonly (dNLS (27.0 ± 1.64 %) and dNLSd343 (26.5 ± 
0.05 %)) (Figure 25A). However, the average number of dNLS aggregates in individual cell 
decreased in both VCPwt (7.4 ± 0.87) and VCPmut (6.4 ± 1.35) co-transfected cells, compared 
to HAonly co-transfected cells (13.1 ± 1.82) (Figure 25B). Nevertheless, the size of dNLS 
appeared increased in both VCPwt (4.2 ± 0.25 µm2) and VCPmut (4.2 ± 0.24 µm2) co-
transfected cells, compared to HAonly (2.1 ± 0.34 µm2) (Figure 25C, D). No such distinct 
effect was noted in co-transfections of VCPwt (2.9 ± 0.43 µm2) and VCPmut (2.5 ± 0.35 µm2) 
with dNLSd343, suggesting the involvement of IDR2 domain of TDP-43 in VCP interactions, 
and its necessity for TDP-43 aggregate maturation. 
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Figure 25: SH-SY5Y cells co-transfected with mKO2 constructs and wt or mut VCP.  (A) Quantification of 
co-transfected cells harboring aggregates. (B) Average number of aggregates in an individual cell. (C) Average 
aggregate size. (D) SH-SY5Y cells co-transfected with mKO2 constructs and wt or mut VCP. Probed for HA-tag 
and counterstained with DAPI. Scale bars: 10 µm. 
Both, VCP wt and mut co-expressed with dNLS produced aggregates that resulted in enriched 
protein detection in UREA-soluble fraction as seen on Western blot (Figure 26). However, 
dNLSd343 co-transfected with VCP wt produced slightly more insoluble aggregates in 
comparison to VCP mut. 
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Figure 26: Solubility of TDPdNLS and TDPdNLSd343 constructs co-transfected with HA-tagged wt or mut 
VCP. RIPA-soluble and UREA-soluble fractions of SH-SY5Y cells co-transfected with plasmids containing HA-
tagged wt or mut VCP and TDPdNLS or dNLSd343. 
5.2.4. Wild-Type UBQLN2, but Not Its P506T Mutation Decreases Initiation of 
TDP-43 dNLS Aggregate Formation 
The co-expression of wt and mut UBQLN2 with KO2-tagged TDP-43 constructs in SH-SY5Y 
cells was confirmed by western blot analysis of total lysates of the co-transfected cells (Figure 
27). The expression levels of TDPdNLSd343 were the lowest among the TDP-43 constructs. 
 
Figure 27: Total lysates of cells co-transfected with wt or mut UBQLN2 and TDP-43 constructs.  Western 
blot of total lysates of SH-SY5Y cells co-transfected with wt or mut HA-tagged UBQLN2 and TDPwt, dNLS, 
dNLSd343, or KO2only, probed for HA-tag, TDP-43 and GAPDH as loading control. 
Similar to VCPmut, the co-transfection of TDP-43 dNLS construct with UBQLN2mut (39.0 ± 
0.83 %) led to an increased percentage of cells harboring aggregates in comparison to HAonly 
(27.0 ± 1.64 %) or UBQLN2wt (27.0 ± 0.92 %) (Figure 28A). On the contrary, the co-
transfection of dNLSd343 with UBQLN2wt (21.5 ± 1.21 %) resulted in the decreased 
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percentage of cells containing aggregates, as compared to HAonly (26.5 ± 0.05 %) or 
UBQLN2mut (28.1 ± 0.07 %) co-transfected cells. UBQLN2 seems to have an impact on TDP-
43 dNLS aggregate initiation, as the co-transfection of TDP-43 dNLS and UBQLN2wt (6.9 ± 
0.70) extensively decreased the number of dNLS aggregates within the individual cells 
(Figure 28B), though with no effect on the dNLS aggregate size or intracellular distribution 
noted (Figure 28C, D).  
 
 
Figure 28: SH-SY5Y cells co-transfected with mKO2 constructs and wt or mut UBQLN2. (A) Quantification 
of co-transfected cells harboring aggregates. (B) Average number of aggregates in an individual cell. (C) Average 
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aggregate size. (D) SH-SY5Y cells co-transfected with mKO2 constructs and wt or mut UBQLN2. Probed for HA-
tag and counterstained with DAPI. Scale bars: 10 µm. 
The higher percentage of cells with dNLS aggregates, combined with an increased number of 
aggregates in an individual cell co-transfected with UBQLN2mut and dNLS, resulted in a 
higher amount of RIPA-insoluble dNLS aggregates in comparison to co-transfection of dNLS 
and UBQLN2wt (Figure 29). 
 
Figure 29: Solubility of TDPdNLS and TDPdNLSd343 constructs co-transfected with HA-tagged wt or mut 
UBQLN2. RIPA-soluble and UREA-soluble fractions of SH-SY5Y cells co-transfected with plasmids containing 
HA-tagged wt or mut UBQLN2 and TDPdNLS or dNLSd343. 
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6. Discussion 
6.1. TDP-43 Aggregation Model 
Despite the overwhelming majority of ALS cases being characterized by cytoplasmic deposits 
of TDP-43 protein in the affected cells, ALS patients display large phenotypic variability 
(Takeda, Kitagawa, and Arai 2020). As it was proposed for other neurodegenerative diseases, 
pathological and clinical heterogeneity could at least in part originate from distinct structural 
conformations of TDP-43 aggregates (Jaunmuktane and Brandner 2019). Indeed, TDP-43 
deposits extracted from FTD diseased brain displayed distinct densities, morphologies 
neurotoxicity and seeding, associated with disease duration and subtype (Laferrière et al. 
2019). However, studies discerning the impact of mutations of other ALS-associated genes 
on the behavior of TDP-43 aggregates and consequently on the disease heterogeneity are 
lacking. 
Therefore, our study aimed to explore the influence of ALS-related genes and their mutations 
on aggregation pattern of TDP-43 in vitro. First, we developed a TDP-43 aggregation model 
in neuroblastoma SH-SY5Y cell line. To ensure cytoplasmic localization of TDP-43, we deleted 
NLS from the full-length sequence. As physiological TDP-43 oligomerization via its N-
terminal domain spatially separates aggregation-prone LCD (Afroz et al. 2017), we tried to 
disrupt the conformation of TDP-43 oligomers by truncating its C-terminal sequence. The 
TDP-43 fragments were designed based on the borders of TDP-43 LCD segments determined 
by Schmidt and colleagues (Schmidt, Barreau, and Rohatgi 2019). Like others (Ishii et al. 
2017; Zhang et al. 2013), we showed that full-length wild-type TDP-43 only rarely forms 
aggregates when expressed in cultured cells. Moreover, in accordance with the literature 
(Zhang et al. 2013), our expressed dNLS readily aggregated in the cytoplasm, forming 
numerous small aggregates, in about a quarter of transfected cells. However, dNLSd343 
expression, despite lower expression levels, caused inclusion formation in a third of 
transfected cells, though at reduced number compared to dNLS, yet with much larger 
inclusion average size. This observation suggests that elimination of IDR2 from TDP-43 
changes its (dNLSd343) propensity for LLPS and aggregate formation, possibly driving the 
aggregate maturation into larger insoluble inclusions. The removal of CR in dNLSd299 in our 
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study did not completely abolish aggregate formation as approximately 7 % of transfected 
cells exhibited few large inclusions. On the other hand, a deletion of the whole LCD in TDP-
43 (dNLSd267) resulted in similar levels of aggregate formation as in control cells. 
Expression of TDP-43 dNLS and dNLSd343 exhibited two dissimilar yet distinct aggregation 
patterns: dNLS displayed numerous dispersed and small aggregates and dNLSd343 fewer 
large bulk aggregates. Therefore, we intended to further investigate both of them in the 
context of the influence ALS-associated genes may have on TDP-43 aggregation. However, 
since deletion of the extreme C-terminal could have major effects on TDP-43 properties, we 
decided to do some additional experiments in order to explore the behavior of TDPdNLSd343 
in SH-SY5Y and RPE-1 cell lines.  
Early studies have demonstrated that 25 kDa and 35 kDa C-terminal fragments of TDP-43 
have the ability to sequester wild-type TDP-43 into cytoplasmic aggregates (Nonaka et al. 
2009; Che et al. 2015). In order to test whether dNLSd343 cytoplasmic accumulations are 
able to sequester wild-type TDP-43 despite lacking the extreme C-terminal region, we 
established a SH-SY5Y FlpIn cell line with an inducible fluorescently tagged wild-type TDP-
43 and transfected the cells with BFP-TDPdNLSd343 construct. Indeed, mCherry-TDPwt 
protein was detected in BFP-TDPNLSd343 cytoplasmic aggregates, while no such effect was 
seen in cells transfected with either BFP-TDPwt or BFPonly. However, this outcome could be 
cell-type dependent that is why we performed a similar experiment with RPE-1 cells 
constitutively expressing TDP-43mRuby2. Still, BFP-TDPwt and BFPonly did not have any 
influence on the cellular localization of TDP-43mRuby2, while BFP-TDPdNLSd343 
sequestered TDP-43mRuby2 into cytoplasmic inclusions. These observations confirmed that 
the lack of the amino acid residues at the extreme C-terminus does not prevent interactions 
of wild-type TDP-43 with TDPdNLSd343 construct and their evolvement into aggregates.   
Mounting evidence suggests that cytoplasmic accumulations of TDP-43 exhibit prion-like 
characteristics (Nonaka and Hasegawa 2020), such as the ability to further induce 
aggregation of the pathological inclusions, which has already been demonstrated in vitro 
(Nonaka et al. 2013; Ding et al. 2015; Gasset-Rosa et al. 2019) and in vivo in mouse model 
(Porta et al. 2018). As TDPdNLSd343 displayed a very prominent and reliable pattern of 
aggregation, we wanted to test, whether this aggregation could be spread among cells in the 
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culture. To this end, we designed two types of experiments with RPE-1 cells; a co-culture 
experiment, were a recipient cell population with fluorescently tagged wild-type TDP-43 
would grow in co-culture with donor cells, transiently transfected with BFP-TDPdNLSd343 
and a supernatant experiment, where BFP-TDPdNLSd343 aggregates would originate from a 
supernatant, taken from transiently transfected cells, that would be added to recipient cells 
constitutively expressing fluorescently tagged wild-type TDP-43. In both of the experiments, 
aggregates were able to transfer among cells; however, no subsequent widespread 
aggregation in the recipient cells could be detected. RPE-1 cells were cultured in the presence 
of Palbociclib, an inhibitor of the cyclin-dependent kinases (CDKs) 4 and 6, which prevents 
progression from G1 to S phase of cell cycle (DeMichele et al. 2015) and inhibits their growth. 
Culturing cells in the arrested state allowed us to have a model, similar to neurons in vivo, 
which are thought to be terminally differentiated and lack the ability to divide (Zhu, Raina, 
and Smith 1999). Additionally, culturing cells in the arrested state prevented a possible 
dilution of aggregates due to cell division.  
The co-culture experiment revealed a slow and steady rise of percentage of cells positive for 
both, BFP and mRuby2 signals. However, TDP-43mRuby2 was never found in cytoplasmic 
aggregates, uptaken by the recipient cells and the aggregation was not exacerbated 
throughout the culture. The apparent inertness of the aggregates suggests that they are 
enveloped in a membrane, which prevents contacts with the endogenous proteins. Similar 
conclusions could be drawn from the supernatant experiment. While some TDP-43mRuby2 
protein was co-localized with BFP-TDPdNLSd343 aggregates uptaken by the recipient cells, 
the percentage of cells harboring aggregates slowly declined and in 6 days, almost no cells 
displayed any aggregates. These findings corroborate the observations from co-culture 
experiment and indicate that the aggregates are degraded by the recipient cell.  
To test this hypothesis, we compared staining of Lamp2 in RPE-1 cells directly transfected 
with TDPdNLSd343 and those incubated with supernatant from RPE-1 cells transfected with 
TDPdNLSd343. Lamp2 is a major component of the lysosomal membrane, and is classified as 
type I transmembrane protein (Alessandrini, Pezzè, and Ciribilli 2017). Our results have 
shown that TDPdNLSd343 aggregates expressed in the RPE-1 cells were not Lamp2 positive 
and thus not inside lysosomal vesicles. We hypothesize that they are not enveloped in a 
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membrane, which would allow endogenously expressed TDP-43, constantly shuttling 
between nucleus and cytoplasm (Ayala et al. 2008), to interact with the cytoplasmic 
aggregates and get sequestered. However, this preposition still needs to be confirmed by 
specific membrane markers such as FM1-43. On the other hand, aggregates uptaken from the 
supernatant into RPE-1 cells were Lamp2 positive, which means that they were enveloped in 
a membrane and on the path of degradation. The membrane enveloping the aggregates 
prevents interactions of the endogenously expressed TDP-43 with the aggregates, which 
could explain why no widespread aggregation was induced in the recipient cells.    
Similar lack of seeded aggregation was observed in a recent study of TDP-43 transfer 
between differentiated SH-SY5Y cells (Sackmann, Sackmann, and Hallbeck 2020). The N-
terminal TDP-43 fragment (1-314 a.a.) from their donor cells formed cytoplasmic puncta in 
the recipient cells, however, no reliable co-localization with full-length TDP-43 expressed by 
the recipient cells could be confirmed (Sackmann, Sackmann, and Hallbeck 2020). 
Additionally, while numerous studies have demonstrated intercellular transmission of TDP-
43 protein and its derivatives (Nonaka et al. 2013; Ding et al. 2015; Feiler et al. 2015; 
Smethurst et al. 2016; Zeineddine et al. 2017; Ishii et al. 2017; Porta et al. 2018; Gasset-Rosa 
et al. 2019; Sackmann, Sackmann, and Hallbeck 2020), only introduction of patient-derived 
brain extracts from FTD-diseased brains into brains of transgenic mice expressing 
cytoplasmic human TDP-43, has resulted in a widespread aggregation throughout 
neuroanatomic connectome (Porta et al. 2018). This is indicating that complex biological 
processes, involving multiple components of the nervous system are necessary for 
productive spreading of TDP-43 aggregation.  
6.2. The Impact of ALS-Associated Genes hnRNPA1, MATR3, VCP and 
UBQLN2 on the Severity of TDP-43 Aggregation 
 To study how ALS-associated genes influence TDP-43 aggregation, we selected four different 
genes involved in ALS pathogenesis, each of them with a distinctive role within the cell. All of 
the ALS-associated genes in their wild-type and mutant form were co-expressed with TDP-
43wt, dNLS, dNLSd343 and KO2only in SH-SY5Y cells. The expression of all transfected 
constructs was confirmed by western blotting. Interestingly, even though co-transfections of 
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ALS-associated genes’ constructs with dNLSd343 displayed expression at low levels, as 
compared to other TDP-43 constructs, they produced higher percentage of transfected cells 
with aggregates.  
Notably, hnRNPA1 is a member of hnRNP protein family, involved in splicing, mRNA 
stabilization, miRNA biogenesis and transcriptional regulation (Bekenstein and Soreq 2013; 
Howard et al. 2018; Roy et al. 2017; Kattuah et al. 2019). Remarkably, co-transfection of 
either hnRNPA1wt or mut with dNLS or dNLSd343 resulted in decreased number of co-
transfected cells harboring either dNLS or dNLSd343 aggregates. Co-expression of both dNLS 
and dNLSd343 with hnRNPA1 in cells resulted in much less numerous, smaller and more 
rounded aggregates, suggesting these proteins in dense phase could be dynamically 
exchanged with the surrounding proteins in more diluted phase.  This observation was also 
confirmed by preparation of UREA-soluble fractions, where co-transfection of cells with 
dNLS and hnRNPA1wt almost completely eliminates TDP-43 proteins from insoluble fraction 
(UREA fraction), whereas the co-transfection of cells with dNLS and hnRNPA1mut results in 
minor increase of TDP-43 protein levels in the insoluble fraction (UREA-soluble), indicating 
the role of ALS-mutation in the formation of more insoluble aggregates. This is consistent 
with previously discussed data, where co-transfection of cells with dNLS and hnRNPA1wt 
resulted in greatly decreased size of dNLS aggregates, while the decrease in size of dNLS 
aggregates in cells co-transfected with hnRNPA1mut was not as pronounced. Absence of 
dNLSd343 co-expressed with wt or mut hnRNPA1 in UREA-soluble fraction confirms findings 
that dNLSd343 aggregates formed in the cells co-transfected with hnRNPA1wt or mut are 
much smaller and thus possibly more soluble. 
It has been shown, that hnRNPA1 can form reversible amyloid fibrils described as dynamic 
states of protein assemblies with high free energies (Gui et al. 2019). Together with the fact 
that C-terminal part of TDP-43 directly interacts with C-terminal domain of hnRNPA1 
(Buratti et al. 2005) and that they co-phase separate (Gasset-Rosa et al. 2019), we can 
speculate that their interactions promote more homogeneous dissolution of proteins with 
less dense dynamic structures. Moreover, a recent study of TDP-43 aggregates using atomic 
force microscopy has shown that TDP-43 fragments lacking C-terminal domain form smaller 
aggregates compared to full-length protein (French et al. 2019). This is consistent with the 
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notion that TDP-43-hnRNPA1 intermolecular interactions via their C-terminal domains 
spatially separate aggregation-prone LCDs and reduce the number of large aggregates, as 
observed in our study. Interestingly, even though hnRNPA1 undergoes LLPS and can form 
irreversible fibrils, which are enhanced by ALS-linked mutation D262V (Kim et al. 2013; 
Molliex et al. 2015; Lin et al. 2015), we could not detect any cytoplasmic accumulation of 
either hnRNPA1wt or mut by microscopy. There was, however, a difference in the number of 
cells containing aggregates between the cells co-transfected with TDP-43 dNLSd343 and 
hnRNPA1wt or hnRNPA1mut, indicating the promoting effect of hnRNPA1 D262V mutation 
on driving dNLSd343 LLPS towards aggregate formation. 
MATR3 is also an RNA-binding protein, localized in nuclear matrix and involved in various 
tasks concerning nucleic acids such as chromatin organization, DNA replication, 
transcription and repair, RNA processing, transport, stability and alternative splicing (Salton 
et al. 2011; 2010; Coelho et al. 2015; Attig et al. 2018; Zhao et al. 2018). Co-transfection of 
MATR3 bearing S85C mutation with either TDP-43 dNLS or dNLSd343 increased the number 
of cells with aggregates in comparison with MATR3wt or control plasmid co-transfections. 
As shown previously, lower levels of RNA promote LLPS of RNA-binding proteins (Maharana 
et al. 2018) and TDP-43 assemblies lacking RNA are insoluble (Mann et al. 2019; Gasset-Rosa 
et al. 2019). Expression of MATR3 with S85C mutation increases retention of mRNA in the 
nucleus (Boehringer et al. 2017), possibly leading to higher tendency of TDP-43 dNLS and 
dNLSd343 to phase-separate and tipping the balance towards their insoluble inclusions. 
Additionally, N-terminal sequence of MATR3 exhibits low complexity and is able to undergo 
phase separation to form liquid-like droplets in the nucleus (Iradi et al. 2018; Gallego-Iradi 
et al. 2019). Introduction of MATR3 S85C mutation inhibits droplet formation (Gallego-Iradi 
et al. 2019; Malik et al. 2018), possibly providing us with an explanation for increased size of 
TDP-43 dNLS aggregates, especially in cells co-transfected with MATR3wt. Indeed, increased 
levels of dNLS in cells co-transfected with dNLS and MATR3wt detected in UREA-soluble 
fraction compared to cells co-transfected with dNLS and MATR3mut, corroborate this 
proposition. 
In contrast to previously discussed proteins mainly associated with RNA processes, one VCP’s 
main duties is facilitating proteasomal degradation of damaged or misfolded proteins by 
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binding to polyubiquinated proteins and delivering them to proteasome complex (Ye, Meyer, 
and Rapoport 2001; Meyer and Weihl 2014; Ye et al. 2017). Soluble TDP-43 is degraded 
primarily by the ubiquitin proteasome system, whereas removal of TDP-43 aggregates 
requires autophagy (Scotter et al. 2014). Therefore, it is not surprising that co-expression of 
mutant VCP gene with TDP-43 dNLS and dNLSd343 resulted in an increased proportion of 
transfected cells with dNLS and dNLSd343 aggregates, respectively. Increased number of 
aggregates was possibly initiated by the interference of defective VCP in with the degradation 
pathway of mutated TDP-43. However, co-expressing VCPwt with TDP-43 dNLS and 
dNLSd343 did not reduce the percentage of transfected cells with aggregates, even though 
VCP is supposed to prevent aggregation (Song, Wang, and Li 2007), suggesting an upper limit 
of proteolytic machinery to degrade misfolded proteins. In addition to VCP role in protein 
clearance, other functions have also been ascribed to it, such as its involvement in cellular 
stress response, i.e. affecting stress granule assembly (Seguin et al. 2014) and clearance 
(Buchan et al. 2013; B. Wang et al. 2019). Stress granules also assemble by LLPS (Dobra et al. 
2018) and are RNA-protein aggregates known to contain TDP-43 and other ALS-related 
proteins (Colombrita et al. 2009; Dewey et al. 2011; Liu-Yesucevitz et al. 2010; McDonald et 
al. 2011; Vance et al. 2013) that are thought to represent precursors of pathological 
cytoplasmic inclusions (Dewey et al. 2012), similar as modelled by our constructs. Therefore, 
the role of VCP in stress granule disassembly could explain its inhibitory effect on the number 
and promoting effect on the size and insolubility of dNLS aggregates in comparison with 
controls. Recently published data revealed that under hyperosmotic stress VCP along with 
other proteasome-interacting proteins forms nuclear proteasomal foci behaving as liquid 
droplets (Yasuda et al. 2020). In light of this study, VCP could actively participate in altering 
the conditions for dNLS LLPS and thus changing the dNLS aggregate properties. 
Like VCP, UBQLN2 participates in proteolytic processes such as delivering ubiquitinated 
proteins to the proteasome. Besides, it is also involved in autophagy, cell signaling, cell cycle 
progression and cytoskeletal association (Zhang et al. 2014). Similarly, co-transfection of 
cells with UBQLN2 carrying P506T mutation with TDP-43 dNLS, resulted in increased 
percentage of aggregates in transfected cells, when compared to control or UBQLN2wt co-
transfected cells. Probably similar tampering of UBQLN2 mutant with TDP-43 degradation 
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machinery took place. However, co-expressing TDP-43dNLSd343 with UBQLN2wt led to 
decreased percentage of transfected cells harboring aggregates, suggesting possible ability 
of UBQLN2wt to boost degradation of dNLSd343. In addition to its other functions, UBQLN2 
associates with stress granule components and regulates their formation by delaying 
initiation processes (Alexander et al. 2018). Later could explain for the reduced number of 
aggregates in UBQLN2wt and TDP-43dNLS co-transfected cells. Additionally, UBQLN2 itself 
undergoes LLPS (Dao et al. 2018) and its ALS-associated mutations change its LLPS 
properties, affect its solubility and promote its oligomerization (Dao et al. 2019). This is 
consistent with the observed increased percentage of cells harboring aggregates and their 
increased insolubility upon co-transfection of cells with UBQLN2mut and dNLS. The detected 
co-localization of dNLS aggregates with UBQLN2mut indicates possible reciprocal influence 
on their tendencies to phase separate. However, since UBQLN2mut had no effect on 
dNLSd343 aggregation pattern, this is suggesting that the lacking amino acid residues could 
be crucial for the cooperation of TDP-43 and UBQLN2 during LLPS and initial stages of 
aggregate formation. 
Over the recent years, the extent of ALS heterogeneity as well as its clinical, pathological and 
genetic overlap with several other neurodegenerative disorders has become increasingly 
evident (Taylor, Brown, and Cleveland 2016). Nevertheless, research studies usually focus 
on individual genes or processes, neglecting the need to connect pathological pathways with 
the disease onset and progression. Our study shows that each of the investigated ALS-
associated genes has a unique impact on TDP-43 aggregation, implicating the importance of 
their pathways on disease severity and progression (Figure 30). It could be even argued, that 
each ALS-linked gene we co-transfected with aggregation-prone construct led to the 
formation of distinct “aggregate type,” similar to those identified by Laferrière and colleagues 
(Laferrière et al. 2019), which could represent the basis for disease heterogeneity.  
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Figure 30: Summary of TDP-43 aggregate types in co-transfected SH-SY5Y cells. Full red shapes 
represent TDP-43 aggregates, twisted lines represent soluble TDP-43, and orange and yellow shapes represent 
TDP-43 aggregates co-localized with UBQLN2. 
However, determining the influence of ALS-associated genes on aggregation pattern of TDP-
43 remains the first step in elucidating the mechanisms of TDP-43 aggregation. It would be 
important to confirm these differences in TDP-43 aggregation patterns directly in the 
aggregates extracted from postmortem tissue or from motor neurons derived from ALS 
patients with distinct mutations in ALS-associated genes. Additional studies, revealing the 
effects of TDP-43 interactors with the potential to reduce or accelerate TDP-43 aggregation 
in combination with different mutations of ALS-associated genes, are definitely needed. 
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7. Conclusions 
In our study, we sought to explore the influence of ALS-associated genes on TDP-43 
localization and biochemical properties in the context of nucleo-cytoplasmic transport 
disruption. We successfully confirmed both of our hypotheses. 
Expression of genes (UBQLN2, MATR3, VCP and hnRNPA1) linked to ALS affects 
biochemical properties and/or cellular localization of protein TDP-43. 
And 
Nucleo-cytoplasmic transport defect modelling exacerbates pathological changes 
resulting from the expression of a certain ALS mutation.  
We modeled the nucleo-cytoplasmic transport defects by deleting the NLS from TDP-43 
sequence. This resulted in cytoplasmic aggregation of TDPdNLS, specifically: approximately 
a quarter of the transfected SH-SY5Y cells harbored numerous small aggregates. We 
demonstrated that additional shortening of the LCD domain leads to distinct patterns of TDP-
43 aggregation. The most striking was TDPdNLSd343 construct, which displayed aggregates 
in a third of the transfected cells and the aggregates were fewer and bigger in comparison to 
dNLS. We confirmed that despite dNLSd343 lacking the extreme C-terminal part of LCD, it 
has retained the ability to sequester wild-type TDP-43. However, we could not invoke 
widespread aggregation in the recipient cells by performing co-culture and supernatant 
experiments. We propose that a membrane enveloping the aggregates prevents contacts with 
the wild-type protein in the recipient cells. 
 We decided that since both, dNLS and dNLSd343 constructs have shown a distinct and 
prominent aggregation pattern, we would utilize both of them to study the impact selected 
ALS-associated genes have on TDP-43 localization and biochemical properties.  
By co-transfecting dNLS and dNLSd343 constructs with wild-type and mutant ALS-
associated genes, we demonstrated that each of the tested genes has a unique influence on 
TDP-43 aggregation pattern and thus changing its localization, confirming the second part 
of the first hypothesis and solubility of the aggregates, thus changing its biochemical 
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properties and confirming the first part of the first hypothesis. These effects were studied in 
the context of disrupted nucleocytoplasmic transport, which caused exacerbation of 
pathological aggregation following co-transfection with wild-type or mutant ALS-associated 
genes, confirming the second hypothesis. While some of the ALS-associated genes, such as wt 
and mut hnRNPA1 reduced the number of aggregates and increased their solubility, others 
increased the number of aggregates and/or their size and/or decreased their solubility. We 
also show that each of the genes has a unique influence on both dNLS and dNLSd343, 
suggesting that the extreme C-terminus has a prominent role in initiation and maturation of 
the aggregates. Considering all this data, we propose that each ALS-linked gene we studied 
uniquely affects TDP-43 aggregation processes, leading to the formation of distinct 
“aggregate types,” which could represent the basis for disease heterogeneity. 
In summary, our study is first to provide an insight into the impact ALS-associated genes have 
on TDP-43 aggregation. As a part of our research, we developed a TDP-43 aggregation model, 
which could be used in future studies of therapeutical compounds that could potentially 
reduce or eliminate TDP-43 aggregates and thus reverse the pathological changes in the 
affected cells of ALS patients. Our results also underline the significance of comparative 
research in the ALS field and provide an understanding on how different mechanisms 
interact at the molecular level and lead to neurodegeneration that may reveal crucial in 
future for successful development of therapeutics. 
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